EIN Presswire: Merck Live Feed Press Releases

BioMarin to Present at the Robert W. Baird Healthcare Conference

Wed, 08 Sep 2010 13:00:00 +0000

BioMarin to Present at the Robert W. Baird Healthcare Conference

PR Newswire

NOVATO, Calif., Sept. 8 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the Robert W. Baird Healthcare Conference in New York City on Wednesday, September 15, 2010 at 10:30 a.m. ET.

Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, www.BMRN.com. A replay of the call will be archived on the site for one week following the call.

About BioMarin

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises four approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; Kuvan® (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany; and Firdapse™ (amifampridine phosphate), which has been approved by the European Commission for the treatment of Lambert Eaton Myasthenic Syndrome (LEMS). Other product candidates include GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in clinical development for the treatment of MPS IVA and PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase II clinical development for the treatment of PKU. For additional information, please visit www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

BioMarin®, Naglazyme® and Kuvan® are registered trademarks of BioMarin Pharmaceutical Inc.

Firdapse™ is a trademark of BioMarin Huxley Ltd.

Aldurazyme® is a registered trademark of BioMarin/Genzyme LLC.

Contacts:

Investors
Eugenia Shen
BioMarin Pharmaceutical Inc.
(415) 506-6570

SOURCE BioMarin Pharmaceutical Inc.

Reportlinker Adds Brazil Pharmaceutical Market Overview - Expanding healthcare access drives double-digit sales growth

Tue, 07 Sep 2010 15:07:18 +0000

Reportlinker Adds Brazil Pharmaceutical Market Overview - Expanding healthcare access drives double-digit sales growth

PR Newswire

NEW YORK, Sept. 7 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Brazil Pharmaceutical Market Overview – Expanding healthcare access drives double-digit sales growth

http://www.reportlinker.com/p0289303/Brazil-Pharmaceutical-Market-Overview-–-Expanding-healthcare-access-drives-double-digit-sales-growth.html

Introduction

Brazil's retail pharmaceutical market was valued at $12.6 billion in 2009, having grown by 14.3% between 2008 and 2009. Key growth drivers include the expanding population, improved access to healthcare, and the burgeoning middle class which is increasingly opting for branded drugs. Consequently, Big Pharma is targeting Brazil to off-set slowing sales growth in more developed markets.

Scope

*Overview of socioeconomic and demographic trends, healthcare system, regulation, pricing, reimbursement and intellectual property position in Brazil

*Assesses the size of Brazil's pharmaceutical market by prescribing setting, therapy area, leading brands and by leading companies

*Examines Brazil's generics and biosimilars landscape in terms of regulatory issues, level of penetration, key players and degree of brand erosion

*Quantifies Brazil's R&D and manufacturing infrastructure for the leading pharmaceutical companies, including key metrics and domestic M&A analysis

Highlights

Brazil spent 10.8% of its GDP on both retail and hospital prescribed pharmaceuticals in 2009, reflecting the government's changing priorities, prioritizing healthcare including initiatives to expand access to medicines.

Intellectual property protection remains problematic for branded pharma, with issues associated with patent linkage, drawn out patent reviews, conflict between the two agencies involved in assessing patent applications, and the fact that there is no set period of data exclusivity.

Strong market growth in conjunction with improving regulatory standards has led to Brazil becoming a hotbed for investment from both multinational and domestic companies. Big Pharma players are gaining a stronger presence through M&A, expanding operations, and new product launches.

Reasons to Purchase

*Evaluate the evolving regulatory landscape and the impact of pricing and reimbursement controls on market access in Brazil.

*Quantify the size and growth of the prescription pharmaceutical market in Brazil, analyzing key therapy areas, brands and companies.

*Assess drivers and resistors of generic and biosimilars uptake in Brazil.

ABOUT DATAMONITOR HEALTHCARE 2

About the Healthcare Strategic Analysis Team 2

Geographic specific reports: 2

Global issue reports: 2

1. Brazil - Executive Summary 3

Strategic scoping and focus 3

Key findings - healthcare drivers and resistors in Brazil 4

Brazil - Socio-demographic and economic analysis 7

Socio-demographic trends 7

Socioeconomic trends 8

Brazil - Healthcare system and drug regulatory analysis 11

Brazil healthcare expenditure 11

Brazil healthcare system overview 12

Brazil regulatory issues 13

Brazil pricing and reimbursement issues 13

Brazil - Prescription pharmaceutical sales analysis 15

Pharmaceutical market size 15

Leading therapy areas 15

Leading pharmaceutical brands 15

Leading pharmaceutical companies 15

Brazil - Drug expiry analysis 17

Brazil retail generics market 17

Brazil brand erosion post patent expiry 17

Brazil biosimilars market 17

Brazil - Pharmaceutical Industry Infrastructure analysis 19

Pharmaceutical industry infrastructure overview 19

Related reports 21

Upcoming related reports 21

TABLE OF CONTENTS 22

2. Brazil - Socio-demographic and economic analysis 23

Key findings 23

Socio-demographic trends 23

Socioeconomic trends 23

Demographic trends in Brazil 25

Brazil's population expected to expand rapidly, peaking in 2040 26

Declining number of births with improving infant mortality rates 28

The Brazilian population is slowly aging 29

The Brazilian population is living longer 30

Disease burden in Brazil 31

Heart disease a leading cause of death in Brazil as in more developed markets 32

Violence and social deprivation still significant despite progress 33

An unexpectedly high rate of prostate cancer deaths representative of gaps in healthcare provision 34

Political climate 35

The end of the Lula government but his legacy will live on 35

The effect of the global economic crisis has been felt less in Brazil 36

PAC gives Brazil much needed infrastructure development 36

Is the Brazilian economy in danger of overheating? 37

Debt reduction a fundamental feature of Lula's economic policy 38

Increased prosperity has brought income disparities 41

Business environment 41

Setting up business in Brazil can be complex and difficult 41

The Brazilian tax system is complicated and confusing 42

Workforce is extensive but poorly educated 42

3. Brazil - Healthcare system and drug regulatory analysis 44

Key findings 44

Brazil healthcare expenditure 44

Brazil healthcare system overview 44

Brazil regulatory issues 45

Brazil pricing and reimbursement issues 45

Healthcare system 47

Healthcare expenditure in Brazil is rising 47

Growing cost pressures may lead to a cut in the medication budget 49

Healthcare is delivered through two systems 50

The SUS provides universal healthcare coverage in Brazil 51

SUS management has become less centralized 52

Private health insurance system - most Brazilians use the SUS, but the private health segment is expanding 53

Brazil has sought to expand healthcare coverage to reduce inequalities 54

The Family Health Program reduces burden on hospitals and specialist care 54

The Popular Pharmacy program was set up to increase the supply of medicines to the poor 55

Regulatory issues in Brazil 56

Drug approval and regulatory processes - pharma companies regard Brazil's regulatory environment as unpredictable 56

ANVISA is the national body in charge of regulating medicines in Brazil 56

Similares are being phased out - bioequivalence studies are required for generic drugs in Brazil since 2003 57

Plant inspections are causing lengthy approval times in Brazil 57

ANVISA introduces a new decree on pharmacovigilance 58

Intellectual property protection in Brazil 58

The speed of patent review is slow and backlogs exist 58

There is conflict between the two agencies involved in assessing patent applications 59

There is no set period of data exclusivity in Brazil 59

Compulsory licenses on HIV/AIDS drugs were used only as a threat until May 2007 60

Pipeline patents have awarded several HIV/AIDS drugs extra protections but could be overruled in the future 61

Drug counterfeiting is on the rise in Brazil 61

Drug importation - imported pharmaceuticals have to be registered with ANVISA 62

Pricing and reimbursement in Brazil 63

Pricing issues in Brazil 63

Pricing of new drugs is controlled by the CMED 63

Prices of marketed pharmaceuticals are controlled through price freezes and increases 64

Antiretroviral therapies are priced low in Brazil 65

Reimbursement issues in Brazil - Reimbursable pharmaceuticals are included on the National list of Essential Medicines 66

The Pharmaceutical Care in Primary Healthcare program provides access to essential drugs 67

Strategic program for pharmaceutical assistance includes medicines for neglected diseases 67

The Specialist Pharmaceutical Assistance Component provides specialist and high-cost medicines 68

Despite the SUS reimbursement programs, many patients still do not have access to medicines 68

4. Brazil - Prescription pharmaceutical sales analysis 70

Key findings 70

Pharmaceutical market size 70

Leading therapy areas 70

Leading pharmaceutical brands 70

Leading pharmaceutical companies 70

Pharmaceutical market size in Brazil 72

Leading therapy areas in Brazil 74

Central nervous system was the largest therapy area in terms of sales 76

Musculoskeletal drugs have shown the fastest growth rates 76

Urology and metabolic have shown the slowest growth rates 77

Leading pharmaceutical brands in Brazil 78

Top-selling drug Dorflex sees its franchise extended with follow-up product 81

Cialis to maintain momentum thanks to lifecycle management strategy 81

Lipitor is expected to continue reaching high sales even after patent expiration 81

Leading pharmaceutical companies in Brazil 82

Sanofi-Aventis is now the leading pharma company in Brazil following its acquisition of Medley 83

Novartis's Brazilian retail sales growth driven by its Diovan franchise 84

The leading domestic companies are exhibiting double-digit growth rates 86

EMS 87

Eurofarma 87

Neo Quimica 88

5. Brazil - Drug expiry analysis 89

Key findings 89

Brazil retail generics market 89

Brazil brand erosion post patent expiry 89

Brazil biosimilars market 89

Brazilian generics market dynamics 91

Similares versus true generics 92

Brazilian generics volume uptake 94

Brazilian generics value uptake 95

Brazilian generics market size 96

Drivers and resistors in the Brazilian generics market 97

Several legislative measures have driven generic uptake 98

Loose patent regulations lead to increased market potential for generic players 99

Market pressures drive down generics prices below the mandatory 35% discount 99

International pressures could hamper generics importers 100

Similares provide affordable healthcare, but bioequivalence legislation has fueled the uptake of true generics 100

Key generics players in the Brazilian market 101

Acquiring local generics players is key strategy for foreign players to penetrate the Brazilian market 102

Sanofi-Aventis extends its dominance in Brazil 103

Pfizer seeks to extend its presence in Brazil 104

Valeant acquires two Brazilian generic drug companies 105

Lupin committed to gaining ground in Brazil 105

Opportunities for the generics industry 106

Small molecule brand erosion in the Brazilian market 107

Number of generic entrants by therapy area 107

Brazil biosimilars market dynamics 108

Drivers and resistors of biosimilar growth in Brazil 108

Rising healthcare costs 108

Biosimilars approval process enacted in 2005 109

Indian-based companies dominate the market 109

New and future biosimilar launches 111

Opportunities for the biosimilar industry 112

Monoclonal antibody therapies could soon face biosimilar incursion in Brazil 113

Biosimilars in development internationally 115

6. Brazil - Pharmaceutical Industry Infrastructure analysis 116

Key findings 116

Pharmaceutical industry infrastructure overview 116

Key company infrastructure in Brazil 117

EMS 118

Novartis 121

Ache Labs 125

Medley 128

Sanofi-Aventis 128

Eurofarma 131

Pfizer 134

Bayer Schering 138

Castro Marques 141

Merck & Co. 143

7. Bibliography 147

Brazil - Executive summary 147

Publications and online articles 147

Brazil - Socio-demographic and economic analysis 148

Publications and online articles 148

Datamonitor reports and products 151

Brazil - Healthcare systems and regulations 151

Publications and online articles 151

Datamonitor reports and products 155

Brazil - Prescription pharmaceutical sales 155

Publications and online articles 155

Brazil - Drug expiry analysis 156

Publications and online articles 156

Datamonitor reports and products 159

Brazil - Pharmaceutical industry infrastructure analysis 160

Publications and online articles 160

Datamonitor reports and products 161

APPENDIX 162

Exchange rates used in this report 162

Datamonitor prescription pharmaceutical definition and therapy area classification 163

About Datamonitor 164

About Datamonitor Healthcare 164

Datamonitor consulting 164

Disclaimer 165

Disclaimer 166

List of Tables

Table 1: Brazil - changes in the key value drivers of the Brazilian pharmaceutical market, 2005-09 5

Table 2: Brazil - demographic indicators, 2005 and 2010 8

Table 3: Brazil - key economic indicators, 2005-2012 10

Table 4: Brazil - healthcare expenditure indicators, 2006-09 12

Table 5: Brazil - a range of pricing and reimbursement tools are used, 2010 14

Table 6: Brazil - retail sales and volume of the pharmaceutical market $ and IMS Standard Units), 2009 16

Table 7: Brazil -key metrics for the retail generics and biosimilars market, 2010 18

Table 8: Brazil - R&D and manufacturing infrastructure data, 2010 20

Table 9: Brazil - demographic indicators, 2005 and 2010 25

Table 10: Brazil - top 10 causes of mortality, 2004 31

Table 11: Brazil - disability-adjusted life years (DALY) rates compared to Australia, Japan, the other BRIC nations, North America, and the five major EU markets (5EU), 2009 32

Table 12: Brazil - key economic indicators, 2005-2012 36

Table 13: Brazil - healthcare expenditure indicators, 2006-09 49

Table 14: Brazil - key health system indicators, 2000-09 51

Table 15: Brazil - a range of pricing and reimbursement tools are used, 2010 63

Table 16: Brazil - retail sales and volume of the pharmaceutical market $ and IMS Standard Units), 2009 73

Table 17: Brazil - retail pharmaceutical sales by therapy area ($m and %), 2005-09 75

Table 18: Brazil - retail pharmaceutical volume by therapy area (SUm and %), 2005-09 76

Table 19: Brazil - retail sales growth for top 20 pharmaceutical brands ($m and %), 2009 79

Table 20: Brazil - retail volume growth for top 20 pharmaceutical brands (SUm and %), 2009 80

Table 21: Brazil - retail sales growth for the leading international pharmaceutical companies ($m and %), 2009 84

Table 22: Brazil - retail volume growth for the leading international pharmaceutical companies (SUm and %), 2009 85

Table 23: Brazil - retail sales growth for the leading Brazil-based pharmaceutical companies ($m and %), 2009 86

Table 24: Brazil - retail volume growth for the leading Brazil-based pharmaceutical companies (SUm and %), 2009 87

Table 25: Brazil -key metrics for the retail generics and biosimilars market, 2010 90

Table 26: Brazil - comparison of generic penetration versus other major pharmaceutical markets ($ billion and %), 2007-08 (retail market only for Brazil) 91

Table 27: Brazil - retail sales of the leading generics companies, 2009 101

Table 28: Brazil - healthcare expenditure indicators, 2006-09 108

Table 29: Brazil - a comparison of biosimilar prices in four government tender bids in Brazil 110

Table 30: Brazil - retail sales of biologics (both brands and biosimilars), 2009 111

Table 31: Brazil - retail sales of branded monoclonal antibodies, 2009 113

Table 32: Brazil - retail sales growth for the leading international pharmaceutical companies ($m and %), 2009 117

Table 33: Brazil - EMS's R&D and manufacturing infrastructure, 2010 118

Table 34: Brazil - EMS's R&D and manufacturing infrastructure data compared with other top 10 companies in Brazil, 2010 119

Table 35: Brazil - Novartis's R&D and manufacturing infrastructure, 2010 121

Table 36: Brazil - Novartis's R&D and manufacturing infrastructure data compared with other top 10 companies in Brazil, 2010 122

Table 37: Brazil - Ache Labs's R&D and manufacturing infrastructure, 2010 125

Table 38: Brazil - Ache Labs's R&D and manufacturing infrastructure data compared with other top 10 companies in Brazil, 2010 126

Table 39: Brazil - Sanofi-Aventis's (post acquisition of Medley) R&D and manufacturing infrastructure, 2010 128

Table 40: Brazil - Sanofi-Aventis's (post acquisition of Medley) R&D and manufacturing infrastructure data compared with other top 10 companies in Brazil, 2010 129

Table 41: Brazil - Sanofi-Aventis's Brazilian-based M&A activity, 2008-2010 130

Table 42: Brazil - Eurofarma's R&D and manufacturing infrastructure, 2010 131

Table 43: Brazil - Eurofarma's R&D and manufacturing infrastructure data compared with other top 10 companies in Brazil, 2010 132

Table 44: Brazil - Pfizer's R&D and manufacturing infrastructure (post-acquisition of Wyeth), 2010 134

Table 45: Brazil - Pfizer's R&D and manufacturing infrastructure data compared with other top 10 companies in Brazil, 2010 135

Table 46: Brazil - Bayer Schering's R&D and manufacturing infrastructure, 2010 138

Table 47: Brazil - Bayer Schering's R&D and manufacturing infrastructure data compared with other top 10 companies in Brazil, 2010 138

Table 48: Brazil - Castro Marques's R&D and manufacturing infrastructure, 2010 141

Table 49: Brazil - Castro Marques's R&D and manufacturing infrastructure data compared with other top 10 companies in Brazil, 2010 141

Table 50: Brazil - Merck & Co.'s R&D and manufacturing infrastructure, 2010 143

Table 51: Brazil - Merck & Co.'s R&D and manufacturing infrastructure data compared with other top 10 companies in Brazil, 2010 144

Table 52: Currency exchange rates, 2010 162

Table 53: ATC (anatomical therapeutic chemical) classification codes assigned to a given therapy area within the prescription pharmaceutical market 163

List of Figures

Figure 1: Brazil - key value drivers of Brazil's pharmaceutical market, 2009 4

Figure 2: Brazil - drivers and resistors facing branded pharmaceutical companies 6

Figure 3: Brazil - population and population growth rate, 1950-2050 26

Figure 4: Brazil - population growth compared to Australia, Japan, the other BRIC nations, North America and five major EU markets (5EU), 1950-2050 27

Figure 5: Brazil - birth rates per 1,000 individuals compared to Australia, Japan, the other BRIC nations, North America and the five major EU markets (5EU), 1950-2050 28

Figure 6: Brazil - proportion of population over 65 years compared to Australia. Japan, the other BRIC nations, North America and the five major EU markets (5EU), 1950-2050 29

Figure 7: Brazil - life expectancy compared to Australia, Japan, the other BRIC nations, North America and the five major EU markets (5EU), 1950-2050 30

Figure 8: Brazil - gross domestic product (GDP) per capita growth rate compared with Australia, Japan, the other BRIC nations, North America and the five major EU markets (5EU), 2005-09 38

Figure 9: Debt trap rankings for the Brazil, the UK, France, Germany, Italy, Spain, US, Canada, Australia and Japan, 2010 39

Figure 10: Total debt against GDP, and total cost of servicing debt against total government expenditure (minus annual budget balance) in Brazil, Japan, UK and US ($ billion), 2009 40

Figure 11: Unemployment rates in Brazil, the five major EU markets, North America, Japan, Australia and the other BRIC nations, 1990-2008 42

Figure 12: Brazil - proportion of GDP expenditure on healthcare is significantly higher than for the other BRIC nations, 2006 47

Figure 13: Brazil - structure of the healthcare system, 2008 50

Figure 14: Brazil - three funding schemes for drugs reimbursed by the Unified Health System (Sistema Unico de Saudi; SUS) 66

Figure 15: Brazil - relative retail sales and volume of the Brazilian retail pharmaceutical market (indexed against volume or value in 2005), 2005-09 72

Figure 16: Brazil - retail pharmaceutical sales by therapy area (%), 2005-09 74

Figure 17: Brazil - retail sales growth for the leading retail pharmaceutical brands($m and %), 2009 78

Figure 18: Brazil - retail sales growth for leading pharmaceutical companies (%), 2005-09 82

Figure 19: Brazil - aggregation of retail sales between 2005 and 2009 to demonstrate the affect of Sanofi-Aventis's acquisition of Medley 83

Figure 20: Brazil - volume (%) and value (%) of true generic retail and hospital sales as a share of total Brazilian pharmaceutical sales, 2004-09 93

Figure 21: Brazil - comparison of generic value uptake versus other major pharmaceutical markets (%). 2007-08 94

Figure 22: Brazil - comparison of generic value uptake in Brazil versus other pharmaceutical markets, 2007-08 95

Figure 23: Brazil - comparison of generics market size versus other pharmaceutical markets ($ billion), 2007-08 (retail market only for Brazil) 96

Figure 24: Brazil - drivers and resistors to generic uptake, 2010 97

Figure 25: Brazil - example of typical generic packaging 98

Figure 26: Brazil - benefits and challenges of achieving greater market access through acquisition 102

Figure 27: Brazil - aggregation of retail sales between 2005 and 2009 to demonstrate the affect of Sanofi-Aventis's acquisition of Medley 103

Figure 28: Brazil - Medley provides significant diversification of Sanofi-Aventis's Brazilian portfolio, 2009 104

Figure 29: Brazil - branded retail sales at risk of generic erosion ($m), 2010-13 106

Figure 30: Brazil - yearly generic entry across Anatomical Therapeutic Chemical-1 (ATC-1) groupings within a 5 year period, 2000-07 107

Figure 31: Brazil - total number of cancer cases, 2009-2015 109

Figure 32: Brazil - retail sales ($m) of marketed biologics due to come off-patent, 2010-2015 112

Figure 33: Brazil - drivers and resistors to biosimilar monoclonal antibody entry, 2010 114

Figure 34: Brazil - key biosimilars in development internationally by product class, 2010 115

Figure 35: Brazil - EMS's pharmaceutical operations, 2010 120

Figure 36: Brazil - Novartis's presence compared with other top 10 companies in Brazil 123

Figure 37: Brazil - Novartis's pharmaceutical operations, 2010 124

Figure 38: Brazil - Ache's pharmaceutical operations, 2010 127

Figure 39: Brazil - Sanofi-Aventis's (post acquisition of Medley) pharmaceutical operations, 2010 130

Figure 40: Brazil - Eurofarma's pharmaceutical operations, 2010 133

Figure 41: Brazil - Pfizer's presence (post-merger with Wyeth) compared with other top 10 companies in Brazil 136

Figure 42: Brazil - Pfizer's pharmaceutical operations (post-merger with Wyeth), 2010 137

Figure 43: Brazil - Bayer Schering's presence compared with other top 10 companies in Brazil 139

Figure 44: Brazil - Bayer Schering's pharmaceutical operations, 2010 140

Figure 45: Brazil - Castro Marques's pharmaceutical operations, 2010 142

Figure 46: Brazil - Merck & Co.'s presence compared with other top 10 companies in Brazil 145

Figure 47: Brazil - Merck & Co.'s pharmaceutical operations, 2010 146

To order this report:

Pharmaceutical Industry: Brazil Pharmaceutical Market Overview – Expanding healthcare access drives double-digit sales growth

Pharmaceutical Business News

More Market Research Report

Check our Company Profile, SWOT and Revenue Analysis!

CONTACT:
Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker

Reportlinker Adds US Vaccines Market

Tue, 07 Sep 2010 14:45:55 +0000

Reportlinker Adds US Vaccines Market

PR Newswire

NEW YORK, Sept. 7 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

US Vaccines Market

http://www.reportlinker.com/p0288102/US-Vaccines-Market.html

US demand to grow 5.5% annually through 2014

Demand for vaccines is forecast to increase 5.5 percent annually to more than $14 billion in 2014. The market has experienced dramatic growth due to increasing routine seasonal influenza immunization and the rising number of preventive and booster vaccines available for adults and adolescents. This growth will be compounded as several new therapeutic vaccines for cancer reach the market, followed in the coming years by biological treatments for Respiratory Syncytial Virus (RSV) and Alzheimer's Disease, and a variety of new vaccines for travel and biodefense.

New routine vaccines to boost adult, adolescent segment

Pediatric vaccines have been the mainstay of the vaccine market for many years, growing steadily as new products emerged and as a greater number of routine vaccinations were encouraged. Now, a substantial number of primary vaccines and boosters are being recommended for adolescents and older adults, and the market for vaccines has expanded dramatically with the addition of these populations to the target markets for vaccine producers. Significant growth in the market has been fueled by the introduction of a vaccine for Human Papillomavirus (HPV), recommended for girls and young women and now being considered for males and a wider age range. Seasonal influenza vaccination is also gaining ground and represents a substantial portion of growth in adult vaccines, as new preventive treatments against zoster and meningococcal disease. Also a factor in adult vaccines is the growing use of boosters against tetanus, diphtheria, pertussis and other diseases.

Combination vaccines to pace pediatric products

Among vaccines for children, sales will be affected by the expiration of patent protection for many of the most widely used vaccines. This has encouraged producers to develop several new combination vaccines, which will serve to maintain the value of products while decreasing the burden of multiple individual injections. Traditional DTaP (diphtheria, tetanus, pertussis) vaccines are being supplemented by products for Hepatitis B and polio or Haemophilus b. Also being developed are vaccines to address a wider range of bacterial serotypes, as with Wyeth's blockbuster PREVNAR7, which has been expanded to address 13 serotypes and which is recommended as a supplement for children who already received the earlier vaccine. Relatively new vaccines, such as that for Rotavirus, continue to mature and to reach greater immunization coverage.

Many new therapeutic vaccines showing promise

Vaccine demand will be spurred considerably by a number of therapeutic vaccines for cancer that are nearing completion of clinical trials and are poised for FDA approval. There are currently 50 cancer vaccines in phase III or later trials, and the activity surrounding cancer vaccine development is expected to continue at a high pace. Also showing promise are vaccines being developed for RSV, HIV and Alzheimer's Disease. Similarly, a range of vaccines for travel, developing countries and biodefense are in the pipeline, including prophylactics for malaria, hemorrhagic fevers, West Nile virus and plague.

Study coverage

This new industry study presents historical demand data (1999, 2004 and 2009) plus forecasts for 2014 and 2019 by major and minor product group. The study also considers market environment factors, details industry structure, evaluates company market share and profiles 17 industry participants.

INTRODUCTION viii

I. EXECUTIVE SUMMARY 1

II. MARKET ENVIRONMENT 4

General 4

Macroeconomic Outlook 5

Demographic Patterns 8

Health Care Trends 11

Health Insurance & Reimbursement 12

Medical Conditions 14

Chronic Conditions 15

Acute Conditions 17

Reportable Diseases 19

National Health Expenditures 22

Medical Facilities & Professionals 24

Patient Activity 27

Animal Health Care 30

Animal Demographic Trends 31

Veterinarians & Other Veterinary Workers 32

Animal Health Expenditures 33

Regulatory Considerations 36

Human Vaccines Regulation 36

Animal Vaccines Regulation 38

III. VACCINE TECHNOLOGIES 39

General 39

Technologies Used in Currently Licensed Products 40

Technologies Under Development 44

Delivery 45

Valence & Combined Vaccines 46

Efficacy 47

IV. PRODUCT OVERVIEW 49

General 49

Major Product Groups 50

Human Vaccines 51

Recommended Childhood Immunizations 54

Recommended Adult & Adolescent Immunizations 55

Animal Vaccines 57

Historical Market Trends 58

International Activity & Foreign Trade 59

Human Vaccines Trade 62

Animal Vaccines Trade 63

V. HUMAN VACCINES 65

General 65

Pediatric Vaccines 67

Combination Vaccines 69

Diphtheria-Tetanus-Pertussis (DTaP) 70

Measles-Mumps-Rubella (MMR) 72

Other Combination Vaccines 75

Pneumococcal (PCV) 76

Varicella 78

Rotavirus 80

Hepatitis 82

Haemophilus b (Hib) 84

Pediatric Seasonal Influenza 86

Polio 88

Adult & Adolescent Vaccines 89

Seasonal Influenza Vaccines 91

Human Papillomavirus 95

Tetanus-Diphtheria-Pertussis (Tdap) 97

Meningococcus 99

Pneumococcus 101

Hepatitis 103

Herpes Zoster 104

Other Adult & Adolescent Vaccines 106

Varicella 107

Tuberculosis 108

Lyme Disease 109

Pandemic Influenza Vaccines 110

Biodefense 113

Anthrax 115

Smallpox 117

Travel Vaccines 119

Developmental Vaccines 125

Cancer 127

Prostate Cancer 129

Lung Cancer 130

Other Cancers 131

Other Developmental Vaccines 132

HIV/AIDS 133

Respiratory Syncytial Virus (RSV) 135

Alzheimer's Disease 137

All Other Developmental Vaccines 138

VI. ANIMAL VACCINES 140

General 140

Livestock Vaccines 142

Bovine Vaccines 143

Porcine Vaccines 146

Ovine Vaccines 148

Companion Animal Vaccines 149

Canine Vaccines 151

Feline Vaccines 152

Equine Vaccines 153

Other Companion Animal Vaccines 155

Poultry Vaccines 155

Other Animal Vaccines 158

VII. INDUSTRY STRUCTURE 160

General 160

Market Share 162

Competitive Strategies 164

Mergers & Acquisitions 166

Licensing & Related Agreements 168

Research & Development 173

Manufacturing 174

Marketing & Distribution 175

Company Profiles 177

AstraZeneca plc 178

Baxter International Incorporated 180

Biogen Idec Incorporated 182

Boehringer Ingelheim GmbH 183

Crucell NV 185

Dow Chemical Company 190

DynPort Vaccine Company LLC 192

Emergent BioSolutions Incorporated 194

GenVec Incorporated 197

GlaxoSmithKline plc 199

Heska Corporation 202

Intervet/Schering-Plough Animal Health, see Merck

MedImmune LLC, see AstraZeneca

Merck & Company Incorporated 204

Merial Limited, see Sanofi-Aventis

Novartis AG 210

Pfizer Incorporated 214

PharmAthene Incorporated 218

Sanofi-Aventis 221

VaxGen Incorporated 227

VaxInnate Corporation 229

Wyeth, see Pfizer

Additional Companies Mentioned in the Study 231

LIST OF TABLES

SECTION I -- EXECUTIVE SUMMARY

Summary Table 3

SECTION II -- MARKET ENVIRONMENT

1 Macroeconomic Indicators 8

2 Population & Households 11

3 Health Insurance Coverage of the US Population 14

4 Chronic Conditions by Type 17

5 Acute Conditions by Type 19

6 Specified Reportable Diseases 21

7 National Health Expenditures 24

8 Selected Medical Facilities & Professionals 27

9 Patient Activity 30

10 Animal Population 32

11 Animal Health Employment 33

12 Animal Health Expenditures 35

SECTION III -- VACCINE TECHNOLOGIES

1 US Licensed Vaccines by Production Technology 42

SECTION IV -- PRODUCT OVERVIEW

1 Vaccines Demand by Major Product Group 51

2 Human Vaccines Licensed for US Sale 52

3 2010 CDC-Recommended Childhood Immunizations 55

4 2010 CDC-Recommended Adolescent Immunizations 56

5 2010 CDC-Recommended Adult Immunizations 56

6 Vaccines Market, 1999-2009 59

7 US Trade in Vaccines 62

8 US Trade in Human Vaccines 63

9 US Trade in Animal Vaccines 64

SECTION V -- HUMAN VACCINES

1 Human Vaccines Demand 67

2 Pediatric Vaccines Demand by Type 69

3 Pediatric Combination Vaccines Demand 70

4 Diphtheria, Tetanus & Pertussis (DTaP)

Combination Vaccines Demand 72

5 Measles, Mumps & Rubella (MMR)

Combination Vaccines Demand 75

6 Other Combination Vaccines Demand 76

7 Pediatric Pneumococcal Vaccines Demand 78

8 Varicella Vaccines Demand 80

9 Rotavirus Vaccines Demand 82

10 Pediatric Hepatitis A & B Vaccines Demand 84

11 Haemophilus b (Hib) Vaccines Demand 86

12 Pediatric Seasonal Influenza Vaccines Demand 88

13 Polio Vaccines Demand 89

14 Adult & Adolescent Vaccines Demand by Group & Condition 91

15 Adult & Adolescent Seasonal Influenza Vaccines Demand 95

16 Human Papillomavirus (HPV) Vaccines Demand 97

17 Tetanus-Diphtheria-Pertussis (Tdap) Vaccines Demand 99

18 Meningococcal Vaccines Demand 101

19 Adult & Adolescent Pneumococcal Vaccines Demand 103

20 Adult & Adolescent Hepatitis A & B Vaccines Demand 104

21 Herpes Zoster Vaccines Demand 106

22 Other Adult & Adolescent Vaccines Demand 107

23 Pandemic Influenza Vaccines Demand 113

24 Biodefense Vaccines Demand 115

25 Travel Vaccines Demand 120

26 Developmental Vaccines Demand 127

27 Cancer Vaccines Demand 129

28 Other Developmental Vaccines Demand 133

SECTION VI -- ANIMAL VACCINES

1 Animal Vaccines Demand 141

2 Livestock Vaccines 143

3 Companion Animal Vaccines Demand 150

4 Poultry Vaccines Demand 158

5 Other Animal Vaccines Demand 159

SECTION VII -- INDUSTRY STRUCTURE

1 US Vaccines Revenues by Company, 2009 161

2 Selected Acquisitions & Divestitures 167

3 Selected Cooperative Agreements 171

LIST OF CHARTS

SECTION VII -- INDUSTRY STRUCTURE

1 US Human Vaccines Market Share by Company, 2009 162

2 US Animal Vaccines Market Share by Company, 2009 163

To order this report:

Biotechnology Industry: US Vaccines Market

Biotechnology Business News

More Market Research Report

Check our Company Profile, SWOT and Revenue Analysis!

CONTACT:
Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker

Reportlinker Adds The Cancer Market Outlook to 2015: Competitive landscape, market size, pipeline analysis, and growth opportunities

Tue, 07 Sep 2010 13:54:31 +0000

Reportlinker Adds The Cancer Market Outlook to 2015: Competitive landscape, market size, pipeline analysis, and growth opportunities

PR Newswire

NEW YORK, Sept. 7 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

The Cancer Market Outlook to 2015: Competitive landscape, market size, pipeline analysis, and growth opportunities

http://www.reportlinker.com/p0172209/The-Cancer-Market-Outlook-to-2015-Competitive-landscape-market-size-pipeline-analysis-and-growth-opportunities.html

Global cancer prevalence rates are on the rise owing to an aging population, changing lifestyle and increasing pollution. Prevalence data is significantly influenced by the increasing diagnosis and survival rates across the global market.

The global cancer market is becoming increasingly competitive, with two therapeutic classes namely antineoplastics and cytostatic hormonal treatments dominating this sector. Collectively, the top 10 products in the global cancer market accounted for majority of the revenue in 2009.

Oncology has become one of the major focus areas for pharmaceutical and biotechnology companies because of a high number of unmet needs for improved treatments in different types of cancer. In 2009, around 40,000 Phase I, II and III trials were listed on ClinicalTrials.gov, and approximately 40% of these were related to cancer.

Targeted therapies are revolutionizing the paradigm of cancer treatment and are likely to be used in most cancer patients in the next 10 years. Due to the high incidence and subsequent potential for market success, breast cancer and NSCLC continue to drive high levels of R&D (along with niche indications such as NHL, RCC, CML, and prostate cancer).

Another factor that plays a major role for the growth in the cancer therapy market is expansion of the target indications. Most of the blockbuster drugs were launched for a narrow indication, and were later approved for other indications. A classic example is imatinib, which was first approved by the FDA in 2001 for the treatment of CML and later was expanded to around nine different indications.

Regardless of indication, the key challenge in ensuring the commercial success of pipeline drugs is to ascertain their integration into current treatment regimens either in combination with existing therapies or by demonstrating significant superiority over current treatments. Pricing risk remains the key investment concern in cancer. Moreover, the level of scrutiny by payors regarding the cost-effectiveness of cancer treatments has further intensified in the recent years.

Key Features of this report

• Epidemiological analysis and forecast prevalence of the major cancer indications between 2009-15 including lung, breast, colorectal, and ovarian cancer markets.

• Forecasts and analysis of the major products in the cancer market between 2009-15 spread across the major indications and classes of treatments.

• Overview of key events in the global cancer market that have impacted treatment trends and sales potential across the major cancer indications.

• Strategic and growth analysis of leading pharmaceutical corporations based on sales focus by drug class, currently marketed products and R&D product portfolios.

• Detailed analysis across major classes of cancer treatments including antineoplastics and cytotoxic hormone therapies.

• Detailed analysis of the clinically differentiated products in the cancer pipeline by indication and sales forecast of key R&D pipeline products in the global cancer market.

Key Benefits of this report

• Develop insight into patient potential with the report's coverage of major indications in the cancer segment, the seven largest geographic pharmaceutical markets and the 10 largest companies active in the cancer segment today

• Understand how recent events are affecting the performance of major products, and how their marketers are confronting competitive changes in the cancer marketplace

• Gain up-to-date competitive intelligence across the cancer indications and understand the major issues affecting key pharmaceutical/biotech players

• Understand which indications have the greatest potential to provide franchise growth, and how pharmaceutical companies are attempting to exploit these opportunities

• Compare the franchises of top pharmaceutical marketers across major indications, and understand how market share of leading companies will change over the next 6 years

• Use head-to head comparisons of the leading cancer pipeline compounds to understand which companies will have a presence among key indications over the next 6 years

Key findings of this report

The global cancer market in 2009 was valued at around $50bn, an increase of nearly 6% over previous year sales, and is forecast to grow at a CAGR of more than 7% between 2009–15.

Antineoplastics formed the leading drug class for cancer treatment. While competition is strong within the antineoplastic market, four drugs dominated the global antineoplastics market – Roche's Avastin (bevacizumab), MabThera (rituximab), and Herceptin (trastuzumab), and Novartis's Glivec (imatinib).

Cytostatic hormone therapies formed the other major drug class in the global cancer market, which was led by cytostatic aromatase inhibitors, cytostatic gonad hormone analogs and cytostatic anti-androgens. Arimidex and Femara remained the leading drugs in cytostatic hormone therapy registering Y-o-Y growth of around 3% and 15% respectively in 2009.

In 2009, monoclonal antibodies (mAbs) accounted for the majority of sales, achieving almost 30% share among the top 10 brands in the global cancer market. This was largely driven by the commercial success of the mAb brands: MabThera, Avastin, and Herceptin.

Roche was the leading player in the cancer market in 2009, with its leading products Avastin, MabThera, Herceptin, Tarceva and Xeloda.

Although a large number of cancer vaccines are in development, Dendreon's Provenge (sipuleucel-T) is the first therapeutic cancer vaccine which was approved in the US (April 2010) for the treatment of prostate cancer.

The top 10 true generic players in the cancer market represented 70% of the total generic market in 2009. Teva followed by Hospira remained the market leaders in the generic cancer market.

Key questions answered by this report

• What will be the major growth indications and the accompanying growth drivers in the cancer market over the next 6 years?

• Who were the leading players in the cancer market in 2009?

• Which products will be the future growth drivers for the cancer market?

• Which therapeutic categories are forecast to have the highest levels of commercial potential over the period 2009–15?

• Which indications are forecast to have the highest levels of market potential over the period 2009–15?

• What is the competitive landscape of key therapeutic areas?

• Which companies are best positioned to succeed in the cancer market over the period 2009–15?

• What are the significant market and pipeline developments that may shape corporate strategies for leading drug majors in this market?

• How is the generic market performing?

• How are the top 10 generic players positioned in the cancer market?

About Business Insights 2

Disclaimer 2

Executive summary 15

Overview and epidemiology of cancer indications 15

Global market analysis 16

Pipeline analysis 16

Competitive landscape 17

Chapter 1 Scope and methodology 19

Scope 19

Key cancer indications covered in this report 19

Methodology 20

Chapter 2 Overview and epidemiology of cancer indications 21

Summary 21

Introduction 22

Overview 22

Cancer risk factors 22

Lung cancer 24

Overview 24

Diagnosis, treatment and management 25

Epidemiology 26

NSCLC 26

SCLC 27

Forecast epidemiology 28

NSCLC 28

SCLC 29

Colorectal cancer 31

Overview 31

Diagnosis, treatment and management 31

Epidemiology 32

Forecast epidemiology 33

Breast cancer 35

Overview 35

Diagnosis, treatment and management 35

Epidemiology 36

Forecast epidemiology 37

Ovarian cancer 39

Overview 39

Diagnosis, treatment and management 40

Epidemiology 40

Forecast epidemiology 41

Uterine and cervical cancer 43

Overview 43

Diagnosis, treatment and management 43

Epidemiology 44

Forecast epidemiology 44

Leukemia 46

Overview 46

Diagnosis, treatment and management 47

Epidemiology 47

Forecast epidemiology 48

Prostate cancer 50

Overview 50

Diagnosis, treatment and management 50

Epidemiology 51

Forecast epidemiology 52

Pancreatic cancer 54

Overview 54

Diagnosis, treatment and management 54

Epidemiology 55

Forecast epidemiology 55

Lymphomas 57

Overview 57

Diagnosis, treatment and management 57

Epidemiology 58

Forecast epidemiology 59

Head and neck cancer 61

Overview 61

Diagnosis, treatment and management 62

Epidemiology 63

Forecast epidemiology 63

Chapter 3 Global market analysis 65

Summary 65

Introduction 65

Market analysis by country 66

Market analysis by drug class 68

Leading brand dynamics 69

Avastin (bevacizumab) – Roche 70

MabThera (rituximab) – Roche 72

Herceptin (trastuzumab) – Roche 73

Glivec/Gleevec (imatinib) – Novartis 74

Taxotere (docetaxel) – Sanofi-Aventis 75

Leading brands by type of cancer 76

Key recent events in the cancer market 79

Antineoplastics 82

Competitive dynamics of antineoplastics 82

Leading antineoplastic brands 84

Antineoplastic mAb market analysis 85

Market dynamics 85

Key brands analysis 85

Antineoplastic protein kinase inhibitors 87

Market dynamics 87

Key brands analysis 87

Vinca alkaloid market analysis 88

Market dynamics 88

Key brands analysis 88

Anti-metabolites 88

Market dynamics 88

Key brands analysis 89

Platinum compounds 89

Market dynamics 89

Key brands analysis 89

Antineoplastic sales forecast 90

Cytostatic hormonal therapies 91

Competitive dynamics of cytostatic hormonal therapies 91

Leading brands of cytostatic hormonal therapies 92

Cytostatic aromatase inhibitors market analysis 93

Market dynamics 93

Key brands analysis 94

Cytostatic gonadotrophin-releasing hormone analog market analysis 95

Market dynamics 95

Key brands analysis 95

Cytostatic anti-androgens 96

Market dynamics 96

Key brands analysis 96

Cytostatic hormonal therapy sales forecast 97

Global cancer market sales forecast 98

Generic cancer market 99

Chapter 4 Pipeline analysis 103

Summary 103

Introduction 104

Key trends in R&D 104

Targeted therapies are changing the treatment regimen of cancer 104

Cancer vaccines enhance the body's immune response 105

Pricing is becoming a major issue for cancer patients 105

Combination treatments are becoming the treatment of choice 106

Oncology pipeline 107

Leading drugs in development 108

Recently approved/marketed drugs 110

Afinitor (everolimus) – Novartis 110

Arzerra (ofatumumab) – GSK/Genmab 111

Votrient (pazopanib) – GSK 114

Provenge (sipuleucel-T) – Dendreon 116

Trastuzumab-DM1 (T-DM1) – Roche 117

Phase III compounds 120

Stimuvax (emepepimut- S) – Merck Serono 120

Ipilimumab (MDX-010) – Bristol Myers Squib (BMS) 122

Omnitarg (pertuzumab) – Roche 124

Abiraterone – Johnson & Johnson (J&J) 126

BSI-201(iniparib) – Sanofi-Aventis 128

Pipeline forecast of leading drugs in development 130

Factors affecting forecasts 130

Chapter 5 Competitive landscape 131

Summary 131

Introduction 132

Sales performance of leading players 132

Roche 134

Sales focus by drug class 135

Regional sales distribution 135

Marketed product portfolio 136

Pipeline analysis 138

Strategic and growth analysis 140

Drivers of growth 140

Resistors of growth 141

Novartis 142

Sales focus by drug class 142

Regional sales distribution 143

Marketed product portfolio 144

Pipeline analysis 145

Strategic and growth analysis 147

Drivers of growth 147

Resistors of growth 147

Sanofi-Aventis 148

Sales focus by drug class 148

Regional sales distribution 149

Marketed product portfolio 150

Pipeline analysis 151

Strategic and growth analysis 153

Drivers of growth 153

Resistors of growth 154

AstraZeneca 154

Sales focus by drug class 154

Regional sales distribution 155

Marketed products portfolio 156

Pipeline analysis 157

Strategic and growth analysis 158

Drivers of growth 158

Resistors of growth 159

Eli Lilly 160

Sales focus by drug class 160

Regional sales distribution 160

Marketed products portfolio 161

Pipeline analysis 162

Strategic and growth analysis 163

Drivers of growth 163

Resistors of growth 164

Competitive positioning of top true generic players in the cancer market 165

Appendix 167

IMS data 167

Antineoplastic and immunomodulating agents 167

L1: Antineoplastics 167

L2: Cytostatic hormone therapy 167

Forecast factors 167

Epidemiology forecast: 167

Market forecast: 167

Glossary 168

Abbreviations 168

Trial expansions 171

Table of figures

Figure 1: Treatment of lung cancer by stage 25

Figure 2: Types of breast cancers 35

Figure 3: Types of leukemia 46

Figure 4: Chemotherapy options for Hodgkin's disease 58

Figure 5: Head and neck cancers and their risk factors 62

Figure 6: 7MM cancer market share by region (%), 2009 67

Figure 7: Relative positions of the 7MM in the global cancer market, 2009 68

Figure 8: Current pharmacological treatment options for cancer 107

Figure 9: Oncology pipeline by indication and stage of development, 2010 108

Figure 10: Key drugs in late-stage development or that have been recently launched 109

Figure 11: Contribution of the top 10 players to growth of the global cancer market, 2008–09134

Figure 12: Roche's cancer sales by drug class ($m), 2009 135

Figure 13: Novartis' cancer sales by drug class ($m), 2009 143

Figure 14: Sanofi-Aventis' cancer sales by drug class ($m), 2009 149

Figure 15: AstraZeneca's cancer sales by drug class ($m), 2009 155

Figure 16: Competitive positioning of the top 10 true generic players in the 7MM, 2009 166

Table of tables

Table 1: Estimated prevalence of NSCLC across the seven major markets, 2009 27

Table 2: Estimated prevalence of SCLC across the seven major markets, 2009 28

Table 3: Forecast epidemiology of NSCLC across the seven major markets, 2009-15 29

Table 4: Forecast epidemiology of SCLC across the seven major markets, 2009-15 30

Table 5: Estimated prevalence of colorectal cancer across the seven major markets, 2009 33

Table 6: Forecast epidemiology of colorectal cancer across the seven major markets, 2009-15 34

Table 7: Estimated prevalence of breast cancer across the seven major markets, 2009 37

Table 8: Forecast epidemiology of breast cancer across the seven major markets, 2009-15 38

Table 9: Estimated prevalence of ovarian cancer across the seven major markets, 2009 41

Table 10: Forecast epidemiology of ovarian cancer across the seven major markets, 2009-1542

Table 11: Estimated prevalence of uterine and cervical cancer across the seven major markets, 2009 44

Table 12: Forecast epidemiology of uterine and cervical cancer across the seven major markets, 2009-15 45

Table 13: Estimated prevalence of leukemia across the seven major markets, 2009 48

Table 14: Forecast epidemiology of leukemia across the seven major markets, 2009-15 49

Table 15: Estimated prevalence of prostate cancer across the seven major markets, 2009 52

Table 16: Forecast epidemiology of prostate cancer across the seven major markets, 2009-1553

Table 17: Estimated prevalence of pancreatic cancer across the seven major markets, 2009 55

Table 18: Forecast epidemiology of pancreatic cancer across the seven major markets, 2009-15 56

Table 19: Estimated prevalence of lymphomas across the seven major markets, 2009 59

Table 20: Forecast epidemiology of lymphomas across the seven major markets, 2009-15 60

Table 21: Estimated prevalence of head and neck cancers across the seven major markets, 2009 63

Table 22: Forecast epidemiology of head and neck cancers across the seven major markets, 2009-15 64

Table 23: Global cancer market by geography ($m), 2009 66

Table 24: Breakdown of the global cancer market by drug class($m), 2009 69

Table 25: Leading brands in the global cancer market ($m), 2009 70

Table 26: Leading brands in breast cancer ($m), 2009 77

Table 27: Leading brands in colon cancer ($m), 2009 77

Table 28: Leading brands in prostate cancer ($m), 2009 78

Table 29: Leading brands in lung cancer ($m), 2009 78

Table 30: Breakdown of the global antineoplastic market by drug class ($m), 2009 83

Table 31: Leading brands in global antineoplastics market ($m), 2009 84

Table 32: Antineoplastic sales forecast ($m), 2009-15 90

Table 33: Breakdown of the global cytostatic hormonal therapies by drug class ($m), 2009 92

Table 34: Leading brands in global cytostatic hormonal therapies market ($m), 2009 93

Table 35: Cytostatic hormonal therapy sales forecast ($m), 2009-15 98

Table 36: Global cancer market sales forecast ($m), 2009–15 99

Table 37: Classification of the generic cancer market in the 7MM ($m), 2009 100

Table 38: Breakdown of the true generics cancer market by drug class in the 7MM ($m), 2009 100

Table 39: Breakdown of the true generics cancer market by drug class in the 7MM, 2009 (mSU) 101

Table 40: Leading true generic cancer drugs in the 7MM ($m), 2009 102

Table 41: An overview of Afinitor 110

Table 42: An overview of Arzerra 111

Table 43: An overview of Votrient 114

Table 44: An overview of Provenge 116

Table 45: An overview of trastuzumab-DM1 117

Table 46: Key recent trials with trastuzumab-DM1 119

Table 47: An overview of Stimuvax 120

Table 48: An overview of ipilimumab 122

Table 49: Key recent trials with ipilimumab 123

Table 50: An overview of Omnitarg 124

Table 51: Key recent trials with Omnitarg 125

Table 52: An overview of abiraterone 126

Table 53:Key recent trials with abiraterone 127

Table 54: An overview of BSI-201 128

Table 55: Sales forecast for leading drugs in development ($m), 2009–15 130

Table 56: Leading players in the global cancer market ($m), 2009 132

Table 57: Regional sales distribution of Roche ($m), 2009 136

Table 58: Roche's leading cancer products ($m), 2009 137

Table 59: Roche's late-stage cancer R&D pipeline, April 2010 139

Table 60: Regional sales distribution of Novartis ($m), 2009 144

Table 61: Novartis' leading cancer products ($m), 2009 145

Table 62: Novartis' late-stage cancer R&D pipeline, July 2010 146

Table 63: Regional sales distribution of Sanofi-Aventis ($m), 2009 150

Table 64: Sanofi-Aventis' leading cancer products ($m), 2009 151

Table 65: Sanofi-Aventis' late-stage cancer R&D pipeline, April 2010 152

Table 66: Regional sales distribution of AstraZeneca ($m), 2009 156

Table 67: AstraZeneca's leading cancer products ($m), 2009 157

Table 68: AstraZeneca's late-stage cancer R&D pipeline, April 2010 158

Table 69: Regional sales distribution of Eli Lilly ($m), 2009 161

Table 70: Eli Lilly's leading cancer products ($m), 2009 162

Table 71: Eli Lilly's late-stage cancer R&D pipeline, April 2010 163

Table 72: Leading true generic players in the 7MM cancer market ($m), 2009 165

To order this report:

Pharmaceutical Industry: The Cancer Market Outlook to 2015: Competitive landscape, market size, pipeline analysis, and growth opportunities

Pharmaceutical Business News

More Market Research Report

Check our Company Profile, SWOT and Revenue Analysis!

Nicolas Bombourg

Reportlinker

Email: nbo@reportlinker.com

US: (805)652-2626

Intl: +1 805-652-2626

SOURCE Reportlinker

Generex Signs Marketing & Distribution Deal for Glucose RapidSpray™ with Merck in Mexico

Tue, 07 Sep 2010 13:30:00 +0000

Generex Signs Marketing & Distribution Deal for Glucose RapidSpray™ with Merck in Mexico

Merck will Market the Product as Diabion® GlucoShot®

PR Newswire

WORCESTER, Mass., Sept. 7 /PRNewswire/ -- Generex Biotechnology Corporation (Nasdaq: GNBT) (www.generex.com), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today announced that it has entered into a long-term marketing and distribution agreement with Merck, S.A. de C.V. in Mexico for the distribution of one of the Company's proprietary over-the-counter products, Glucose RapidSpray™ brand formulated glucose spray product. Merck will market and distribute the product in Mexico as Diabion® GlucoShot®.

Merck is a global pharmaceutical and chemical company with total revenues of EUR 7.7 billion in 2009, a history that began in 1668, and a future shaped by approximately 40,000 (including Merck Millipore) employees in 64 countries. Its success is characterized by innovations from entrepreneurial employees. In Mexico, Merck was founded in 1930 as one of the first pharmaceutical producers. Today, with 1,035 employees, Merck, S.A. de C.V. manufactures and sells a great variety of products for the treatment of pain, diabetes, thyroid problems, colds, growth hormone, multiple sclerosis and cancer, among other illnesses. In its chemical area, Merck has specialty pigments and active ingredients for the cosmetics industry.

Glucose RapidSpray™ (www.GlucoseRapidSpray.com) is a proprietary, innovative alternative for people who require or want additional glucose. Glucose RapidSpray™ delivers a fat-free, low-calorie glucose formulation that was developed using the Company's proprietary buccal drug delivery technologies. Glucose RapidSpray™ delivers glucose directly into the mouth where it is absorbed. Glucose RapidSpray™ is simple to carry and use with no large tablets to chew or messy gels to swallow.

Presently, Glucose RapidSpray™ is available in retail pharmacies across Canada, the United States and in independent stores and pharmacies in the Middle East. The processes for registering the product for retail marketing in other countries are underway.

"We are so pleased to enter the expansive Mexican marketplace through this marketing agreement with Merck in Mexico," said Bill Abajian, Sr. Executive Advisor to Generex, Global Licensing and Business Development. "We believe that Glucose RapidSpray™ will become a staple within consumer households as more people become familiar with the benefits of the product. We expect that with the marketing expertise that Merck Serono provides penetration within the Mexican marketplace will open up additional markets for the company's product in Latin and South America as well as the other global markets within which a foothold has already been made."

"We welcome Generex, to proudly contribute to the growth of our diabetes franchise with a world-class technology for our Consumer Health Division with a comprehensive product offering and innovative power," said Dr. Arturro Torres y Gutierrez Rubio, Medical Director for Merck in Mexico. "We will now move quickly to bring together the expertise and complementary capabilities of both Merck and Generex to capture the significant opportunities in the high-growth of the market."

About Generex Biotechnology Corporation

Generex is engaged in the research, development and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist™ device. The Company's flagship product, buccal insulin (Generex Oral-lyn™), which has been approved in India, Lebanon, Algeria, and Ecuador for the treatment of subjects with Type-1 and Type-2 diabetes, is in Phase III clinical trials at several sites around the world. Antigen Express, Inc. is a wholly owned subsidiary of Generex. The core platform technologies of Antigen Express comprise immunotherapeutics for the treatment of malignant, infectious, allergic, and autoimmune diseases. For more information, visit the Generex website at www.generex.com or the Antigen Express website at www.antigenexpress.com.

About Merck in Mexico

Merck Mexico was founded in 1930 as one of the first pharmaceutical producers in Mexico. Today, with close to 1,035 employees, Merck, S.A. de C.V. manufactures and sells a great variety of products for the treatment pain, diabetes, thyroid problems, colds, growth hormone, multiple sclerosis and cancer, among other diseases. In its chemical area, Merck has specialty pigments and active ingredients for the cosmetics industry.

About the Merck Group

Merck is a global pharmaceutical and chemical company with total revenues of EUR 7.7 billion in 2009, a history that began in 1668, and a future shaped by approximately 40,000 (including Merck Millipore) employees in 64 countries. Its success is characterized by innovations from entrepreneurial employees. Merck's operating activities come under the umbrella of Merck KGaA, in which the Merck family holds an approximately 70% interest and free shareholders own the remaining approximately 30%. In 1917 the U.S. subsidiary Merck & Co. was expropriated and has been an independent company ever since.

Safe Harbor Statement

This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," "projects," or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.

SOURCE Generex Biotechnology Corporation

BioMarin to Present at the Morgan Stanley Global Healthcare Conference

Tue, 07 Sep 2010 13:00:00 +0000

BioMarin to Present at the Morgan Stanley Global Healthcare Conference

PR Newswire

NOVATO, Calif., Sept. 7 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the Morgan Stanley Global Healthcare Conference in New York City on Tuesday, September 14, 2010 at 1:00 p.m. ET.

About BioMarin

BioMarin®, Naglazyme® and Kuvan® are registered trademarks of BioMarin Pharmaceutical Inc.

Firdapse™ is a trademark of BioMarin Huxley Ltd.

Aldurazyme® is a registered trademark of BioMarin/Genzyme LLC.

Contacts:

Investors
Eugenia Shen
BioMarin Pharmaceutical Inc.
(415) 506-6570

SOURCE BioMarin Pharmaceutical Inc.

Cardiome Achieves $30 Million Milestone

Thu, 02 Sep 2010 12:00:00 +0000

Cardiome Achieves $30 Million Milestone

PR Newswire

NASDAQ: CRME TSX: COM

VANCOUVER, Sept. 2 /PRNewswire-FirstCall/ - Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced that it has earned a US$30 million milestone payment from its collaboration with Merck (known as MSD outside the United States and Canada), through an affiliate. The milestone was triggered by the recently announced marketing approval for BRINAVESS(TM) (vernakalant (iv)) in the European Union, Iceland and Norway.

"European approval and the milestone payment further strengthen Cardiome's financial position, both in the near term and in the long term via royalties from product sales," said Doug Janzen, Chief Executive Officer and President of Cardiome. "The teams at Merck and Cardiome have done an exemplary job in gaining European regulatory approval for BRINAVESS, and Cardiome is now part of a select group of biotechnology companies who have successfully shepherded a molecule from discovery through to product approval."

Merck Cardiome Agreement

In April 2009, Cardiome and Merck announced a collaboration and license agreement for the development and commercialization of vernakalant. The agreement provides Merck, Sharp and Dohme Corp. (formerly known as Merck & Co., Inc.) with exclusive global rights to vernakalant oral formulation for the maintenance of normal heart rhythm in patients with atrial fibrillation (AF), and provides another Merck affiliate, Merck Sharp & Dohme (Switzerland) GmbH, with exclusive rights outside of the United States, Canada and Mexico to vernakalant IV formulation for rapid conversion of recent onset AF to sinus rhythm in adults.

About Cardiome Pharma Corp.

Cardiome Pharma Corp. is a product-focused drug development company dedicated to the advancement and commercialization of novel treatments for disorders of the heart and circulatory system. Cardiome is traded on the NASDAQ Global Market (CRME) and the Toronto Stock Exchange (COM). For more information, please visit our web site at www.cardiome.com.

Forward-Looking Statement Disclaimer

Certain statements in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including without limitation statements regarding product revenues following Merck's expected launch of BRINAVESS and other statements containing the words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect" and similar expressions. Such forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause our actual results, events or developments, or industry results, to be materially different from any future results, events or developments expressed or implied by such forward-looking statements or information. Risks, uncertainties and factors that could cause such actual events or results expressed or implied by such forward-looking statements and information to differ materially from any future events or results expressed or implied by such statements and information include, but are not limited to, the risks, uncertainties and factors related to the fact that: we, together with our collaborative partners, may not be able to successfully develop all or any of our current or future products and may not be able to obtain regulatory approval in targeted indications for our current or future products in all markets; we may not achieve or maintain profitability; our future operating results are uncertain and likely to fluctuate; we may not be able to raise additional capital as and when required; we depend on our collaborative partners to perform their obligations under licensing or other collaborative agreements; we may not be successful in establishing additional corporate collaborations or licensing arrangements; we may not be able to establish marketing and sales capabilities and the costs of launching our products may be greater than anticipated; any of our products that obtain regulatory approval will be subject to extensive post-market regulation that may effect sales, marketing and profitability; any of our products that are successfully developed may not achieve market acceptance; we rely on third parties for the continued supply and manufacture of our products and have no experience in commercial manufacturing; we may face unknown risks related to intellectual property matters, including with respect to our ability to protect our intellectual property; we face increased competition from pharmaceutical and biotechnology companies; and other factors as described in detail in our filings with the Securities and Exchange Commission available at www.sec.gov and the Canadian securities regulatory authorities at www.sedar.com. Given these risks, uncertainties and factors, you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. All forward-looking statements and information made herein are based on our current expectations and we undertake no obligation to revise or update such forward-looking statements and information to reflect subsequent events or circumstances, except as required by law.

SOURCE Cardiome Pharma Corp.

Epigenetics Therapeutics to 2017 - High Market Potential for Epigenetics Drugs in Acute Myeloid Leukemia, Multiple Myeloma and Cutaneous T-Cell Lymphoma Now Available at ReportsandReports

Thu, 02 Sep 2010 11:29:00 +0000

Epigenetics Therapeutics to 2017 - High Market Potential for Epigenetics Drugs in Acute Myeloid Leukemia, Multiple Myeloma and Cutaneous T-Cell Lymphoma Now Available at ReportsandReports

PR Newswire

DALLAS, September 2, 2010 /PRNewswire/ -- ReportsandReports announces it will carry the Epigenetics Therapeutics to 2017 - High Market Potential for Epigenetics Drugs in Acute Myeloid Leukemia, Multiple Myeloma and Cutaneous T-Cell Lymphoma Market Research Report in its store.

Browse the complete Report on: http://www.reportsandreports.com/market-reports/epigenetics-therapeutics-to-2 017-high-market-potential-for-epig/

Search More Then 45000 Market Research Reports at ReportsandReports (http://www.reportsandreports.com/)

GBI Research's report, "Epigenetics Therapeutics to 2017 - High Market Potential for Epigenetics Drugs in Acute Myeloid Leukemia, Multiple Myeloma and Cutaneous T-Cell Lymphoma", provides in-depth analysis of trends, issues and challenges in this industry. The report analyzes the technology that shapes the industry dynamics for the key geographies: the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan (http://www.reportsandreports.com/). Further, the report provides competitive benchmarking for the leading companies and analyzes the licensing agreements that shape the global markets.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.

    Scope

    The scope of this report includes:

    - Annualized market data from 2001 to 2009, forecast forward to 2016.
    - Analysis of the leading technology in this space
    - Market characterization
    - Key drivers and barriers that have a significant impact on the market.
    - Competitive benchmarking of leading companies.

    Reasons to buy

    The report will enhance your decision making capability. It will allow
    you to

    - Align your product portfolio to the markets with high growth potential.
    - Develop market-entry and market expansion strategies by identifying the
      leading therapeutic segments and geographic markets poised for strong
      growth.
    - Reinforce R&D pipelines
    - Develop key strategic initiatives by understanding the key focus areas
      of leading companies.
    - Exploit in-licensing and out-licensing opportunities by identifying
      products that could fill portfolio gaps.

    Table of Contents

    1.1 List of Tables 5
    1.2 List of Figures 6

    2 Introduction 7
    2.1 GBI Research Report Guidance 7

    3 Market Characterization: Global Epigenetics Market 8
    3.1 Disease Overview 8
    3.1.1 Myelodysplastic Syndrome 8
    3.1.2 Cutaneous T-cell Lymphoma 8
    3.2 Epigenetic Drugs 9
    3.3 The US 11
    3.4 Top Five European Markets 12
    3.5 Japan 14

    4 In-Depth Analysis 16
    4.1 Introduction 16
    4.2 Vidaza (Azacitidine) 16
    4.2.1 Indication 16
    4.2.2 Mechanism of Action 16
    4.2.3 Revenue Forecast 16
    4.2.4 Key Takeaway 23
    4.2.5 Market Potential 23
    4.2.6 Pipeline Analysis 29
    4.2.7 Drug Profile 32
    4.3 Dacogen (Decitabine) 33
    4.3.1 Indication 33
    4.3.2 Mechanism of action 33
    4.3.3 Revenue Forecast 34
    4.3.4 Key Takeaway 39
    4.3.5 Market Potential 39
    4.3.6 Pipeline Analysis 45
    4.3.7 Drug Profile 48
    4.4 Zolinza (Vorinostat) 49
    4.4.1 Indication 49
    4.4.2 Mechanism of Action 49
    4.4.3 Revenue Forecast 49
    4.4.4 Disease Overview 55
    4.4.5 Market Potential 55
    4.4.6 Pipeline Analysis 61
    4.4.7 Drug Profile 63
    4.5 Istodax (Romidepsin) 64
    4.5.1 Indication 64
    4.5.2 Disease Overview 64
    4.5.3 Mechanism of Action 65
    4.5.4 Market Potential 65
    4.5.5 Pipeline Analysis 71
    4.5.6 Clinical Studies by Phases 71
    4.5.7 Clinical Studies by Indication 72
    4.5.8 Drug Profile 73

    5 Competitive Landscape 75
    5.1 Merck & Co. 75
    5.1.1 Company Overview 75
    5.1.2 Business Description 75
    5.1.3 SWOT 77
    5.2 Celgene Corporation 77
    5.2.1 Company Overview 77
    5.2.2 Business Description 78
    5.2.3 SWOT 79
    5.3 EISAI 80
    5.3.1 Company Overview 80
    5.3.2 Business Description 80
    5.3.3 SWOT 82

    6 Epigenetic Therapeutics: Appendix 83
    6.1 Market Definitions 83
    6.2 Abbreviations 83
    6.3 Research Methodology 84
    6.3.1 Coverage 85
    6.3.2 Secondary Research 85
    6.3.3 Primary Research 85
    6.3.4 Forecasts 86
    6.3.5 Expert Panel Validation 88
    6.4 Contact Us 88
    6.5 Disclaimer 88
    6.6 Sources 88

Read Full TOC of Report : http://www.reportsandreports.com/market-reports/epigenetics-therapeutics-to-2 017-high-market-potential-for-epig/

    Browse all Pharmaceuticals Reports at
http://www.reportsandreports.com/market-research/pharmaceuticals/

About Us

ReportsandReports comprises an online library of 10,000 reports, in-depth market research studies of over 5000 micro markets, and 25 industry specific websites. Our client list boasts almost all well-known publishers of such reports across the globe. We as a third-party reseller of market research reports employ a number of marketing tools, such as press releases, email-marketing and effective search-engine optimization techniques to drive revenues for our clients. We also provide 24/7 online and offline support service to our customers.

(Due to the length of these URLs, it may be necessary to copy and paste the hyperlinks into your Internet browser's URL address field. Remove the space if one exists.)

    Contact:
    Ms. Sunita
    7557 Rambler road,
    Suite 727, Dallas, TX 75231
    Tel: +1-888-989-8004
    http://www.reportsandreports.com/
    http://reportsnreports.wordpress.com/
    http://reportsandreports.blogspot.com/

SOURCE MarketsandMarkets

AMM Announces The Doctors' Choice Awards Finalists: Over 4,600 MDs Vote for Best Journal Ads in AMM's Doctors' Choice Awards

Wed, 01 Sep 2010 17:10:26 +0000

AMM Announces The Doctors' Choice Awards Finalists: Over 4,600 MDs Vote for Best Journal Ads in AMM's Doctors' Choice Awards

PR Newswire

MOUNT LAUREL, N.J., Sept. 1 /PRNewswire-USNewswire/ -- The Association of Medical Media (AMM) has announced The Doctors' Choice Awards ad finalists from 21 specialties based on research on advertisements appearing in 2009. The creative teams that worked on the winning advertisements will be recognized at The Doctors' Choice Awards on Thursday, September 16, 2010 from 3:30 – 6:30 p.m. at Comix Comedy Club, located at 353 West 14th Street in New York City.

The research on MD preferences was conducted by computer solicitation on 325 advertisements representing the 86 most widely-advertised products in 2009. The study was conducted by Readex Research, and drew more than 4,600 responses. This is the seventh year AMM has conducted The Doctors' Choice research.

"Given the significance of pharmaceutical developments for patients and professionals alike, we're pleased to continue spearheading The Doctors' Choice Awards," said AMM President Tino DeCarlo. "This program shines a light on truly innovative, effective advertisements, and recognizes the teams that so seamlessly work together to produce pieces intended to catch the eye of general practitioners and specialists across the healthcare spectrum."

The advertisements were judged on their ability to communicate clearly and quickly, help with clinical decisions, prompt seeking more information or re-examining treatment, generate interest, add to information provided by company sales representatives and underscore the value of the product prescribed.

The finalists' advertisements, their manufacturers and the agencies responsible for them are:

CATEGORY	PRODUCT	COMPANY	AGENCY	PAGES
Anesthesiology
	Opana	Endo Pharmaceuticals	Stonefly Communications Group	3
	OxyContin Tablets	Purdue Pharma	LyonHeart	1
	Precedex	Hospira	Goble & Associates	1
Cardiology
	Bystolic	Forest	Sudler & Hennessey	3
	Plavix	Bristol-Myers Squibb/Sanofi Aventis	Torre Lazur McCann	2
	Simcor Tablets	Abbott	Sudler & Hennessey	2
Dermatology
	Epiduo Gel	Galderma	Echo Torre Lazur	1
	ORACEA	Collagenex	Sudler & Hennessey	1
	Vectical	Galderma	Sudler & Hennessey	2
Endocrinology
	Byetta	Amylin Pharmaceuticals	Palio Communications	1
	Levemir	Novo Nordisk	CDM	1
	Welchol	Daiichi Sankyo	Area 23	3
Emergency Medicine
	Plavix	Bristol-Myers Squibb/Sanofi Aventis	Torre Lazur McCann	2
	Tygacil	Wyeth	Ogilvy	2
	Zyvox	Pfizer	CDM	1
General Surgery
	Entereg	Adolor/GlaxoSmithKline	Torre Lazur McCann	2
	Tygacil	Wyeth	Ogilvy	2
	Zyvox	Pfizer	CDM	1
Infectious Disease
	Prezista	Tibotec	ICC	3
	Reyataz	Bristol-Myers Squibb	DraftFCB	3
	Truvada	Gilead	Abelson Taylor	1
Oncology
	AVASTIN	Genentech	Harrison and Star	1
	Herceptin	Genentech BIOONCOLOGY	Flashpoint Medica	1
	Rituxan	Genentech Biogen Idec	Abelson Taylor	1
Ophthalmology
	Combigan	Allergan	Pacific Communications	2
	Lumigan	Allergan	Pacific Communications	1
	XALATAN	Pfizer	Euro RSCG Life LM&P	2
Orthopedic Surgery
	CELESTONE SOLUSPAN	Schering-Plough	Merck	1
	Euflexxa	Ferring Pharmaceuticals	Sudler & Hennessey	1
	Synvisc One	Genzyme	Wishbone	1
Pediatric
	Lexapro	Forest	Grey Healthcare	4
	ProAir	Teva Pharmaceuticals	GSW Worldwide/Intouch Solutions	1
	Rotarix Vaccine	GlaxoSmithKline	DraftFCB	2
Gastroenterology
	HalfLytely	Braintree	LyonHeart	2
	Lialda	Shire US	Euro RSCG	2
	VIREAD	Gilead	Medicus Life Brands	4
Nephrology
	Ferrlecit	Sanofi-Aventis	Saatchi & Saatchi/Healthcare Innovations	1
	Myfortic Tablet	Novartis	Revolution Health	2
	Venofer	American Regent	5 Strong Healthcare	2
Neurology
	AVONEX	Biogen Idec	Euro RSCG Life Metamax	2
	COPAXONE	Teva Neuroscience	Harrison and Star	2
	Tysabri	Biogen Idec	Euro RSCG	4
Physician Assistant / Nurse Practitioners
	Aldara	Graceway	Metaphor	1
	Naprelan	Victory Pharma	Victory Pharma	1
	Yaz	Bayer Healthcare	CommonHealth	2
Rheumatology
	Enbrel	Amgen/Pfizer	Saatchi & Saatchi	2
	Rituxan	Genentech Biogen Idec	AgencyRx	2
	Savella	Forest	Ferguson	3
Urology
	Gelnique	Watson	Core-Create	3
	RAPAFLO	Watson	Wedgewood Communications	4
	Trelstar LA	Watson	Wedgewood Communications	2
Psychiatric
	Geodon	Pfizer	LyonHeart	1
	INVEGA	Janssen	Grey Healthcare	2
	Lexapro	Forest	Grey Healthcare	2
Multi-Specialty
	Kapidex Capsules	TAP Pharmaceuticals	Abelson Taylor	3
	Levemir FlexPen	Novo Nordisk	CDM	1
	Lexapro	Forest	Grey Healthcare	4
Pulmonology
	Tracleer	Actelion	Giant	1
	Ventavis	Actelion	Giant	1
	Zyvox	Pfizer	CDM	1


Obstetricals/ Gynecologicals
	Aldara	Graceway Pharmaceuticals	Metaphor	1
	EVISTA	Lilly	Abelson Taylor	2
	Premarin Vaginal Cream	Wyeth	Harte Hanks	1

At the reception, awards will also be presented to the highest-scoring advertisement.


Highest Scoring Ad Overall Finalists
	AVASTIN	Genentech	Harrison and Star	5
	Lexapro	Forest	Grey Healthcare	2
	Rituxan	Genentech Biogen Idec	Abelson Taylor	1

Tickets for the awards reception are $180 for AMM members and $215 for non-members. Discounts are also available for reservations made for groups of five or ten attendees. Contact AMM at 856-380-6814 for information regarding the event and ticket purchases, or visit the association's Web site at www.ammonline.org.

About the Association of Medical Media

Celebrating its 35th year, the Association of Medical Media (AMM) is dedicated to educating and promoting the value of the medical publishing and communications industry. AMM's name reflects its membership: medical publishing firms, content providers and associated companies in the medical communications field. Through regular networking opportunities and our unique industry partnerships, AMM aims to be the leader in the future development of medical media. For more information, visit www.ammonline.org.

SOURCE Association of Medical Media

Results From Investigator-Sponsored Trials Presented at SSIEM Conference

Wed, 01 Sep 2010 13:00:00 +0000

Results From Investigator-Sponsored Trials Presented at SSIEM Conference

Kuvan Patients Show Improvements in Neurocognitive Functioning, Mood and Behavior

PR Newswire

NOVATO, Calif., Sept. 1 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that results from investigator-sponsored studies on Kuvan (sapropterin dihydrochloride) are being presented at the 2010 Annual Symposium of the Society for The Study of Inborn Errors of Metabolism (SSIEM), August 31st-September 3rd in Istanbul, Turkey. Investigators reported that PKU patients taking Kuvan showed improvements in brain functioning, mood and behaviors.

"While these investigator-sponsored studies were conducted in a small number of subjects, the results indicate benefits beyond lowering blood Phe levels, and we hope to document similar neurocognitive improvements in subjects with PKU in our recently initiated Phase 3b Kuvan outcomes study," said Dr. Hank Fuchs, Chief Medical Officer of BioMarin. "If successful, the data will be submitted in support of a label amendment."

Highlights of Investigator-Sponsored Studies:

Neurocognitive findings in individuals with Phenylketonuria and treatment with sapropterin dihydrochloride (BH4) (White, et al; Washington University, St. Louis): Baseline findings indicate that executive performance is worse for subjects with PKU as compared to non-PKU subjects across a range of executive functions such as inhibitory control, strategic processing and working memory. The results of this exploratory study suggest improvements in executive abilities following treatment with sapropterin.

Brain function in individuals with PKU treated with Kuvan: Evidence from functional magnetic resonance imaging (Christ, et al; University of Missouri-Columbia, USA): At baseline, irregularities in neural activation were observed in subjects with PKU in the prefrontal cortex (PFC) and other brain regions as compared to subjects without PKU. At four weeks, two early-treated PKU participants responded to Kuvan with a >20% reduction in phenylalanine levels and also showed improved activation for a region in the orbitomedial PFC.

Pilot study to evaluate the effects of Kuvan on adult individuals with Phenylketonuria with measurable maladaptive behaviors (Moseley, et al; University of Southern California/Keck School of Medicine): Preliminary six-month data in ten subjects with measurable maladaptive behaviors showed that while there was a small decrease in blood Phe concentrations there was a large decrease in the Phe/Tyr ratio. Additionally, improvements were measured in all negative behaviors, most specifically, irritability and rage.

About Kuvan

Kuvan® (sapropterin dihydrochloride) Tablets are indicated in the United States to reduce blood phenylalanine (Phe) levels in patients with hyperphenylalaninemia (HPA) due to tetrahydrobiopterin- (BH4-) responsive phenylketonuria (PKU). Kuvan is to be used in conjunction with a Phe-restricted diet. The active ingredient in Kuvan, sapropterin dihydrochloride, is the synthetic form of 6R-BH4 (tetrahydrobiopterin), a naturally occurring enzyme cofactor that works in conjunction with phenylalanine hydroxylase (PAH) to metabolize Phe. Kuvan has received orphan drug designation from both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMEA). Kuvan has received seven years of orphan exclusivity in the United States and ten years of market exclusivity in the E.U.

Important Safety Information

Prolonged exposure to elevated blood Phe levels in PKU patients can result in severe neurologic damage. The initiation of KUVAN therapy does not eliminate the need for careful monitoring of blood Phe levels and ongoing dietary management.

Some patients receiving Kuvan can experience significant drops in blood Phe levels. Patients should be monitored closely to ensure that blood Phe levels do not fall too low.

Not all patients with PKU respond to treatment with Kuvan. Response to treatment can only be determined by a therapeutic trial of Kuvan.

Kuvan has not been studied in patients with liver or renal impairment. Patients who have these conditions should be carefully monitored when receiving Kuvan. Caution should be used with the administration of Kuvan to patients who are receiving levodopa and drugs that affect nitric oxide–mediated vasorelaxation or folate metabolism.

The most serious adverse reactions reported during Kuvan administration (regardless of relationship to treatment) were gastritis, spinal cord injury, streptococcal infection, testicular carcinoma, and urinary tract infection. Mild to moderate neutropenia was also noted. The most common adverse reactions were headache, diarrhea, abdominal pain, upper respiratory tract infection, pharyngolaryngeal pain, vomiting, and nausea.

About PKU

PKU, a genetic disorder affecting approximately 50,000 diagnosed patients in the developed world, is caused by a deficiency of the enzyme phenylalanine hydroxylase (PAH). PAH is required for the metabolism of phenylalanine, an essential amino acid found in most protein-containing foods. If the active enzyme is not present in sufficient quantities, Phe accumulates to abnormally high levels in the blood and becomes toxic to the brain, resulting in a variety of complications including severe mental retardation and brain damage, mental illness, seizures, tremors, and limited cognitive ability. As a result of newborn screening efforts implemented in the 1960s and early 1970s, virtually all PKU patients under the age of 40 in developed countries have been diagnosed at birth. To learn more about PKU, please visit www.PKU.com. Information on this website is not incorporated by reference into this press release.

About BioMarin

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises four approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; Kuvan® (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany; and Firdapse™ (amifampridine phosphate), which has been approved by the European Commission for the treatment of Lambert Eaton Myasthenic Syndrome (LEMS). Other product candidates include GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in Phase I/II clinical development for the treatment of MPS IVA and PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase II clinical development for the treatment of PKU. For additional information, please visit www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

BioMarin®, Naglazyme® and Kuvan® are registered trademarks of BioMarin Pharmaceutical Inc.

Firdapse™ is a trademark of BioMarin Huxley Ltd.

Aldurazyme® is a registered trademark of BioMarin/Genzyme LLC.

Contact:
Eugenia Shen
BioMarin Pharmaceutical Inc.
(415) 506-6570

SOURCE BioMarin Pharmaceutical Inc.

MS LifeLines® Reaches Milestone of Servicing One Million In-Bound Calls

Wed, 01 Sep 2010 12:00:00 +0000

MS LifeLines® Reaches Milestone of Servicing One Million In-Bound Calls

Educational Support Service for Multiple Sclerosis Community Provides a Voice at the Other End

PR Newswire

ROCKLAND, Mass. and NEW YORK, Sept. 1 /PRNewswire-FirstCall/ -- EMD Serono, Inc. and Pfizer Inc. (NYSE: PFE) announced today that MS LifeLines, an educational and support service which includes a call center, has achieved a milestone in servicing one million in-bound calls since its inception in 2002. MS LifeLines is sponsored by EMD Serono, Inc. an affiliate of Merck KGaA, Darmstadt, Germany, and Pfizer Inc. The service is available to the multiple sclerosis (MS) community, including people living with MS, their families and care partners.

(Logo: http://photos.prnewswire.com/prnh/20100416/PFIZERLOGO )

(Logo: http://www.newscom.com/cgi-bin/prnh/20100416/PFIZERLOGO )

"As an organization working to deliver innovative solutions, we are pleased to be able to provide our programs and services to the MS community and to continue to enhance all of our offerings," said Fereydoun Firouz, president and chief executive officer of EMD Serono, Inc. "We are proud of our long-standing heritage in serving the MS community, and reaching the one million call milestone is another demonstration of our long-term commitment in MS."

"MS LifeLines is making a difference in the lives of people living with MS," said Paul Richardson, regional president, North America, Pfizer Specialty Care. "This service stands as another example of EMD Serono and Pfizer's commitment to serving the patient communities and advancing treatments for serious diseases."

MS LifeLines was first launched in 2002 as an educational resource for the MS community, sponsored by EMD Serono and Pfizer. One of its service offerings is a call center based in EMD Serono's corporate headquarters in Rockland, Mass. The call center includes patient enrollment specialists, patient support specialists, nurse support specialists and reimbursement specialists. People in the MS community can call any time, day or night and receive assistance. A live representative is available to answer calls 24 hours a day, seven days a week.

"Whether a person calls with a question about therapy or a question related to their insurance, the team at MS LifeLines is here to help lend a hand," added Lauren Sweeney, patient support team member at MS LifeLines. "It is extremely rewarding to be able to make a difference. Receiving a diagnosis of MS can be overwhelming, and we're here to help serve as a resource for the entire MS community."

The programs and services provided by MS LifeLines continue to be enhanced to meet the needs of individuals impacted by MS and their loved ones. A patient access program, MS LifeLines Access Made Simple, was designed to assist eligible patients who need help in getting on therapy quickly. To learn more about the Access Made Simple program, visit www.mslifelines.com. In addition, other innovative service offerings have been introduced including MS LifeLines Rx. This web-based prescribing tool allows physicians to have access to another prescribing option instead of the paper process. For more information on the programs and services offered by MS LifeLines, visit mslifelines.com.

In the US, EMD Serono, Inc. and Pfizer Inc., co-promote Rebif (interferon beta-1a) for the treatment of patients with relapsing forms of multiple sclerosis.

About MS LifeLines®

MS LifeLines is an educational support service committed to the MS community. Our mission is to offer support to people with MS, people on or considering Rebif® (interferon beta-1a) therapy, and the care partners who support them. The web site, www.mslifelines.com, provides information on everything from personal stories to lifestyle tips. MS LifeLines also offers telephone support toll free at 1-877-447-3243.

About Multiple Sclerosis

Multiple sclerosis (MS) is a chronic, inflammatory condition of the central nervous system and is the most common, non-traumatic, disabling neurological disease in young adults. It is estimated that there are approximately 400,000 people in the United States living with MS.

While symptoms can vary, the most common symptoms of MS include blurred vision, numbness or tingling in the limbs and problems with strength and coordination. The relapsing forms of MS are the most common.

About Rebif

Rebif is the only self-administered disease-modifying drug proven effective in reducing MRI lesion area and activity, reducing the frequency of relapses and slowing disability in relapsing MS.+ Rebif is not approved for the treatment of chronic progressive MS.

+The exact correlation between MRI findings and the current or future clinical status of patients, including disability progression, is unknown.

Rebif is used to treat relapsing forms of MS to decrease the frequency of relapses and delay the occurrence of some of the physical disability that is common in people with MS. Rebif is not approved for treatment of chronic progressive MS. Rebif is available in 22 mcg and 44 mcg prefilled, preassembled syringes and a titration pack by prescription only.

Before beginning treatment, patients should discuss with their doctor the potential benefits and risks associated with Rebif. Let your doctor know if you have a history of depression, seizures, liver disease, thyroid problems, or blood cell count or bleeding problems, or if you have had previous allergic reactions to medications. Tell your doctor about all medicines you take, including prescription and non-prescription medicines, vitamins, and herbal supplements. Rebif and other medicines may affect each other causing serious side effects. Talk to your doctor before you take any new medicines. Rebif is not recommended for women who are or plan to become pregnant.

Potential serious side effects of Rebif include depression and risk of suicide, liver problems, risk to pregnancy, injection-site problems, and severe allergic reactions. Allergic reactions are rare and may be associated with difficulty in breathing and loss of consciousness, which require immediate medical attention.

The most common side effects with Rebif are injection-site reactions, flu-like symptoms (fever, chills, muscle aches, tiredness), depression, abdominal pain, increased liver enzymes, and blood cell count decreases. Let your doctor know if you have any of these symptoms or feel sad, tired, hot or cold, or experience hives, rashes, bruising, yellowing of the skin, or a change in body weight (gain or loss).

This information is not intended to replace discussions with your doctor. For additional information about Rebif, please consult the Prescribing Information and Medication Guide at www.emdserono.com and talk to your doctor. You can also visit www.mslifelines.com or call toll-free 1-877-44-REBIF (1-877-447-3243). Rebif is available by prescription only.

About EMD Serono, Inc.

EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt, Germany, is a leader in the US biopharmaceutical arena, integrating cutting-edge science with unparalleled patient support systems to improve people's lives. The company has strong market positions in neurodegenerative diseases, with Rebif® (interferon beta-1a), as well as in endocrinology, with Saizen® (somatropin (rDNA origin) for injection) and Serostim® (somatropin (rDNA origin) for injection). EMD Serono is a leader in reproductive health, with Gonal-f® (follitropin alfa for injection), Luveris® (lutropin alfa for injection) and Ovidrel® Prefilled Syringe (choriogonadotropin alfa injection). In addition, EMD Serono is growing its expertise and presence in the area of oncology, with more than 10 projects currently in development. With a clear focus on the patient and a leadership presence in the biopharmaceutical industry, EMD Serono's US footprint continues to grow, with more than 1100 employees around the country and fully integrated commercial, clinical and research operations in the company's home state of Massachusetts.

For more information, please visit www.emdserono.com.

About Pfizer Inc.: Working together for a healthier world™

At Pfizer, we apply science and our global resources to improve health and well-being at every stage of life. We strive to set the standard for quality, safety and value in the discovery, development and manufacturing of medicines for people and animals. Our diversified global health care portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and many of the world's best-known consumer products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as the world's leading biopharmaceutical company, we also collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us.

To learn more about our commitments, please visit us at www.pfizer.com.

About Merck KGaA

Merck KGaA is a global pharmaceutical and chemical company with total revenues of euro 7.7 billion in 2009, a history that began in 1668, and a future shaped by approximately 40,000 (including EMD Millipore) employees in 64 countries. Its success is characterized by innovations from entrepreneurial employees. Merck's operating activities come under the umbrella of Merck KGaA, in which the Merck family holds an approximately 70% interest and free shareholders own the remaining approximately 30%. In 1917 the U.S. subsidiary Merck & Co. was expropriated and has been an independent company ever since.

For more information, please visit www.merckserono.com or www.merck.de

SOURCE Pfizer Inc.

Reportlinker Adds Hormone Replacement Therapy in Menopause - Pipeline Assessment and Market Forecasts to 2017

Tue, 31 Aug 2010 16:57:17 +0000

Reportlinker Adds Hormone Replacement Therapy in Menopause - Pipeline Assessment and Market Forecasts to 2017

PR Newswire

NEW YORK, Aug. 31 /PRNewswire/ Reportlinker.com announces that a new market research report is available in its catalogue:

Hormone Replacement Therapy in Menopause - Pipeline Assessment and Market Forecasts to 2017

http://www.reportlinker.com/p0254468/Hormone-Replacement-Therapy-in-Menopause---Pipeline-Assessment-and-Market-Forecasts-to-2017.html

Hormone Replacement Therapy in Menopause - Pipeline Assessment and Market Forecasts to 2017

Summary

GlobalData's has released its pharmaceutical and healthcare report, "Hormone Replacement Therapy in Menopause - Pipeline Assessment and Market Forecasts to 2017". The report is an essential source of information and analysis on the global menopause hormone therapy market. The report identifies the key trends shaping and driving the global menopause hormone therapy market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the existing market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global menopause hormone therapy sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts. GlobalData estimated the global hormone therapy (HT) market to be worth $2.4 billion in 2009, indicating a Compound Annual Growth Rate (CAGR) of -5.9% between 2001 and 2009. This decline in the market is mainly attributed to poor patient compliance as a result of the serious safety concerns associated with hormones. By 2017, the market is forecast to be worth $2.8 billion, with a CAGR of 2.2% between 2009 and 2017. The market is restrained by factors such as the poor acceptance of hormone therapies in patients and physicians. Increased interest in low-dose and ultra-low dose hormone therapies are expected to lead to marginal growth of the HT market.

Scope

The report provides information on the key drivers and challenges in the menopause hormone therapy market. Its Scope includes:

- Annualized global menopause hormone therapy market revenues data from 2001 to 2009, forecast for eight years to 2017.

- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends. These drugs are estrogens or progestins (including combination therapies and low-dose therapies), non-hormonal products such as serum estrogen receptor modulators, serotonin reuptake inhibitors, estrogen receptor alpha agonists, among others.

- Analysis of the current and future competition in the global menopause hormone therapy market. The key market players covered are Pfizer, Merck & Co, Amgen, BioSante Pharmaceuticals, Noven Pharmaceuticals, Bionovo, QuatRx Pharmaceuticals and Depomed.

- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.

- Key topics covered include a strategic competitor assessment, market characterization, unmet needs and the implications for the hormone replacement therapy market.

Reasons to buy

The report will enhance your decision making capability. It will allow you to:

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipelines.

- Develop business strategies by understanding the trends shaping and driving the global menopause hormone therapeutics market.

- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global menopause hormone therapeutics market in future.

- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

- What's the next big thing in the global menopause hormone therapy market landscape? – Identify, understand and capitalize.

1 Table of contents 3

1.1 List of Tables 5

1.2 List of Figures 5

2 Hormone Replacement Therapeutics: Introduction 6

2.1 GlobalData Pipeline Report Guidance 7

2.2 Concerns Raised Regarding the Safety of Hormone Therapy 8

2.2.1 WHI study 8

2.2.2 Million Women Study 8

2.2.3 Heart and Estrogen/Progestin Replacement Study (HERS) 9

2.2.4 Women's Angiographic Vitamin and Estrogen (WAVE trial) 9

2.2.5 Women's Estrogen–Progestin Lipid-Lowering Hormone Atherosclerosis Regression Trial (WELLHART trial) 9

2.2.6 Estrogen Replacement and Atherosclerosis (ERA) study 10

2.2.7 WHI Memory Study (WHIMS study) 10

2.2.8 Postmenopausal Estrogen/Progestin Interventions (PEPI) study 10

2.2.9 Scientific Evidence and Perceptions about the Safety and Efficacy of Hormone Therapy 10

2.2.10 Conclusion 12

2.3 Hormone Replacement Therapy Market Size 13

2.4 Hormone Replacement Therapy Market Forecast and CAGR 13

2.5 Drivers and Barriers for the Hormone Replacement Therapy Market 15

2.5.1 Drivers for the Hormone Replacement Therapy Market 15

2.5.2 Restraints for the Hormone Replacement Therapy Market 15

2.6 Opportunity and Unmet Need 16

2.7 Key Takeaway 17

3 Hormone Replacement Therapy Market: Competitive Assessment 18

3.1 Overview 18

3.2 Strategic Competitor Assessment 18

3.3 Product Profile for the Major Marketed and Off-label Products in the Hormone Therapy Market 19

3.3.1 Enjuvia (synthetic conjugated estrogens, B) 19

3.3.2 Femtrace (estradiol acetate) 21

3.3.3 Premarin (conjugated estrogens) 22

3.3.4 Estrace (estradiol) 24

3.3.5 Femring (estradiol acetate vaginal ring) 25

3.3.6 Vagifem (estradiol vaginal tablets) 27

3.3.7 Transdermal and Topical Estrogen Therapy Products for Postmenopausal Use 28

3.3.8 Menostar (estradiol transdermal) 28

3.3.9 Mirena (levonorgestrel-releasing intrauterine system) 30

3.3.10 Prochieve (Progesterone gel) 30

3.3.11 Prempro (Conjugated Estrogens/ Medroxyprogesterone Acetate Tablets) 31

3.4 Key Takeaway 33

4 Hormone Therapy Market: Pipeline Assessment 34

4.1 Overview 34

4.2 Strategic Pipeline Assessment 34

4.2.1 Technology Trends Analytic Framework 34

4.3 Hormone Therapy – Promising Drugs under Clinical Development 36

4.4 Molecule Profile for Promising Drugs under Clinical Development 37

4.4.1 Aprela (Bazedoxifene/Conjugated Estrogen) 37

4.4.2 Serada (Gabapentin, DM-5689) 38

4.4.3 Odanacatib (MK-0822) 38

4.4.4 Ophena (Ospemifene) 39

4.4.5 ALX1-11 (PREOS, parathyroid hormone 1-84 [rDNA origin] injection) 40

4.4.6 Menerba (MF-101) 41

4.4.7 Pristiq (Desvenlaxafine, DVS-233) 42

4.4.8 Mesafem (low-dose paroxetine mesylate) 43

4.4.9 LibiGel (Testosterone gel) 43

4.5 Hormone Therapy Market – Clinical Pipeline by Mechanism of Action 44

4.6 Hormone Therapy Pipeline – Pipeline by Phase of Clinical Development 45

4.6.1 Hormone Therapy – Phase III Pipeline 46

4.6.2 Hormone Therapy – Phase II Pipeline 47

4.6.3 Hormone Therapy – Phase I Pipeline 48

4.6.4 Hormone Therapy – Preclinical Pipeline 49

4.6.5 Hormone Therapy – Discovery Pipeline 50

4.7 Discontinued / Suspended Drugs for Hormone Replacement Therapy 50

4.8 Key Takeaway 51

5 Hormone Replacement Therapeutics Market: Implications for Future Market Competition 52

6 Hormone Therapy Market: Future Players in Hormone Therapy Market 54

6.1 Introduction 54

6.2 Pfizer 54

6.2.1 Company Overview 54

6.2.2 Business Description 55

6.2.3 Hormone Therapeutics Portfolio 56

6.3 Merck & Co. 57

6.3.1 Company Overview 57

6.3.2 Business Description 57

6.3.3 Hormone Therapeutics Portfolio 58

6.4 Amgen 58

6.4.1 Company Overview 58

6.4.2 Business Description 59

6.4.3 Hormone Therapeutics Portfolio 60

6.5 BioSante Pharmaceuticals 60

6.5.1 Company Overview 60

6.5.2 Business Description 60

6.5.3 Hormone Therapeutics Portfolio 61

6.6 Noven Pharmaceuticals 61

6.6.1 Company Overview 61

6.6.2 Business Description 61

6.6.3 Hormone Therapeutics Portfolio 62

6.7 Bionovo, Inc. 62

6.7.1 Company Overview 62

6.7.2 Business Description 62

6.7.3 Hormone Therapeutics Portfolio 63

6.8 QuatRx Pharmaceuticals Company 63

6.8.1 Company Overview 63

6.8.2 Hormone Therapeutics Portfolio 64

6.9 Depomed Inc. 64

6.9.1 Company Overview 64

6.9.2 Business Description 64

6.9.3 Hormone Therapeutics Portfolio 65

7 Hormone Therapeutics Market: Appendix 66

7.1 Definitions 66

7.2 Acronyms 66

7.3 Scope of Pipeline Research 68

7.4 Research Methodology 68

7.4.1 Coverage 69

7.4.2 Secondary Research 69

7.4.3 Forecasting 69

7.4.4 Primary Research 72

7.4.5 Expert Panel validation 72

7.5 Contact Us 72

7.6 Disclaimer 72

7.7 Sources 73

1.1 List of Tables

Table 1: Hormone Therapeutics, Global, Market Revenue ($bn), 2001-2009 13

Table 2: Hormone Therapeutics, Global, Market Forecast ($bn), 2009-2017 14

Table 3: Hormone Replacement Therapy, Most Promising Drugs Under Clinical Development, 2010 36

Table 4: Hormone Therapeutics, Global, Osteoporosis, Phase III Pipeline, 2010 46

Table 5: Hormone Therapeutics, Menopause, Global, Phase III Pipeline, 2010 46

Table 6: Hormone Therapeutics, Osteoporosis, Global, Phase II Clinical Pipeline, 2010 47

Table 7: Hormone Therapeutics, Menopause, Global, Phase II Clinical Pipeline, 2010 47

Table 8: Hormone Therapeutics, Osteoporosis, Global, Phase I Clinical Pipeline, 2010 48

Table 9: Hormone Therapeutics, Menopause, Global, Phase I Clinical Pipeline, 2010 48

Table 10: Hormone Therapeutics, Osteoporosis, Global, Preclinical Pipeline, 2010 49

Table 11: Hormone Therapeutics, Menopause, Global, Preclinical Pipeline, 2010 49

Table 12: Hormone Therapeutics, Osteoporosis, Global, Discovery Pipeline, 2010 50

Table 13: Hormone Therapy, Global, Discontinued Drugs, 2010 50

Table 14: Hormone Therapeutics, Global, Pfizer Pipeline Drugs, 2010 56

Table 15: Hormone Therapeutics, Global, Merck & Co. Pipeline Drugs, 2010 58

Table 16: Hormone Therapeutics, Global, Amgen Pipeline, 2010 60

Table 17: Hormone Therapeutics, Global, BioSante Pipeline, 2010 61

Table 18: Hormone Therapeutics, Global, Noven Pipeline, 2010 62

Table 19: Hormone Therapeutics, Global, Bionovo Pipeline, 2010 63

Table 20: Hormone Therapeutics, Global, QuatRx Pipeline, 2010 64

Table 21: Hormone Therapeutics, Global, Depomed Pipeline, 2010 65

1.2 List of Figures

Figure 1: Hormone Therapeutics, Global, Market Revenue ($bn), 2001-2009 13

Figure 2: Hormone Therapeutics, Global, Market Forecast ($bn), 2009-2017 14

Figure 3: Opportunity and Unmet Need, Hormone Replacement Therapy, 2010 16

Figure 4: Strategic Competitor Assessment of Major Marketed Products, Hormone Therapy, 2010 19

Figure 5: Hormone Therapy, Menopause, Technology Trends Analytic Framework , 2010 34

Figure 6: Hormone Therapy, Menopause, Technology Trends Analytic Framework - Description , 2010 35

Figure 7: Hormone Therapy Market – Clinical Pipeline by Mechanism of Action, 2010 45

Figure 8: Hormone Therapy, Global, Pipeline by Phases of Clinical Development, 2010 45

Figure 9: Implications for Future Market Competition in the Hormone Therapy Market, 2010 52

Figure 10: Hormone Therapy Market, Global, Clinical Pipeline by Company, 2010 54

Figure 11: GlobalData Methodology, 2010 68

Figure 12: GlobalData Market Forecasting Model, 2010 71

Companies mentioned

Pfizer

Merck & Co.

Amgen

BioSante Pharmaceuticals

Noven Pharmaceuticals

Bionovo, Inc.

QuatRx Pharmaceuticals Company

Depomed Inc.

To order this report:

Pharmaceutical Industry: Hormone Replacement Therapy in Menopause - Pipeline Assessment and Market Forecasts to 2017

Pharmaceutical Business News

More Market Research Report

Check our Company Profile, SWOT and Revenue Analysis!

Contact:

Nicolas Bombourg

Reportlinker

Email: nbo@reportlinker.com

US: (805)652-2626

Intl: +1 805-652-2626

SOURCE Reportlinker

Reportlinker Adds Epigenetics Therapeutics to 2017 - High Market Potential for Epigenetics Drugs in Acute Myeloid Leukemia, Multiple Myeloma and Cutaneous T-Cell Lymphoma

Tue, 31 Aug 2010 16:45:29 +0000

Reportlinker Adds Epigenetics Therapeutics to 2017 - High Market Potential for Epigenetics Drugs in Acute Myeloid Leukemia, Multiple Myeloma and Cutaneous T-Cell Lymphoma

PR Newswire

NEW YORK, Aug. 31 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Epigenetics Therapeutics to 2017 – High Market Potential for Epigenetics Drugs in Acute Myeloid Leukemia, Multiple Myeloma and Cutaneous T-Cell Lymphoma

http://www.reportlinker.com/p0286300/Epigenetics-Therapeutics-to-2017-–-High-Market-Potential-for-Epigenetics-Drugs-in-Acute-Myeloid-Leukemia-Multiple-Myeloma-and-Cutaneous-T-Cell-Lymphoma.html

Epigenetics Therapeutics to 2017 – High Market Potential for Epigenetics Drugs in Acute Myeloid Leukemia, Multiple Myeloma and Cutaneous T-Cell Lymphoma

Summary

GBI Research's report, "Epigenetics Therapeutics to 2017 – High Market Potential for Epigenetics Drugs in Acute Myeloid Leukemia, Multiple Myeloma and Cutaneous T-Cell Lymphoma", provides in-depth analysis of trends, issues and challenges in this industry. The report analyzes the technology that shape the industry dynamics for the key geographies: the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Further, the report provides competitive benchmarking for the leading companies and analyzes the licensing agreements that shape the global markets.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.

Scope

The Scope of this report includes:

- Annualized market data from 2001 to 2009, forecast forward to 2016.

- Analysis of the leading technology in this space

- Market characterization

- Key drivers and barriers that have a significant impact on the market.

- Competitive benchmarking of leading companies.

Reasons to buy

The report will enhance your decision making capability. It will allow you to

- Align your product portfolio to the markets with high growth potential.

- Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth.

- Reinforce R&D pipelines

- Develop key strategic initiatives by understanding the key focus areas of leading companies.

- Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps.

1 Table of Contents 3

1.1 List of Tables 5

1.2 List of Figures 6

2 Introduction 7

2.1 GBI Research Report Guidance 7

3 Market Characterization: Global Epigenetics Market 8

3.1 Disease Overview 8

3.1.1 Myelodysplastic Syndrome 8

3.1.2 Cutaneous T-cell Lymphoma 8

3.2 Epigenetic Drugs 9

3.3 The US 11

3.4 Top Five European Markets 12

3.5 Japan 14

4 In-Depth Analysis 16

4.1 Introduction 16

4.2 Vidaza (Azacitidine) 16

4.2.1 Indication 16

4.2.2 Mechanism of Action 16

4.2.3 Revenue Forecast 16

4.2.4 Key Takeaway 23

4.2.5 Market Potential 23

4.2.6 Pipeline Analysis 29

4.2.7 Drug Profile 32

4.3 Dacogen (Decitabine) 33

4.3.1 Indication 33

4.3.2 Mechanism of action 33

4.3.3 Revenue Forecast 34

4.3.4 Key Takeaway 39

4.3.5 Market Potential 39

4.3.6 Pipeline Analysis 45

4.3.7 Drug Profile 48

4.4 Zolinza (Vorinostat) 49

4.4.1 Indication 49

4.4.2 Mechanism of Action 49

4.4.3 Revenue Forecast 49

4.4.4 Disease Overview 55

4.4.5 Market Potential 55

4.4.6 Pipeline Analysis 61

4.4.7 Drug Profile 63

4.5 Istodax (Romidepsin) 64

4.5.1 Indication 64

4.5.2 Disease Overview 64

4.5.3 Mechanism of Action 65

4.5.4 Market Potential 65

4.5.5 Pipeline Analysis 71

4.5.6 Clinical Studies by Phases 71

4.5.7 Clinical Studies by Indication 72

4.5.8 Drug Profile 73

5 Competitive Landscape 75

5.1 Merck & Co. 75

5.1.1 Company Overview 75

5.1.2 Business Description 75

5.1.3 SWOT 77

5.2 Celgene Corporation 77

5.2.1 Company Overview 77

5.2.2 Business Description 78

5.2.3 SWOT 79

5.3 EISAI 80

5.3.1 Company Overview 80

5.3.2 Business Description 80

5.3.3 SWOT 82

6 Epigenetic Therapeutics: Appendix 83

6.1 Market Definitions 83

6.2 Abbreviations 83

6.3 Research Methodology 84

6.3.1 Coverage 85

6.3.2 Secondary Research 85

6.3.3 Primary Research 85

6.3.4 Forecasts 86

6.3.5 Expert Panel Validation 88

6.4 Contact Us 88

6.5 Disclaimer 88

6.6 Sources 88

1.1 List of Tables

Table 1: List of Approved Epigenetic Drugs, 2010 8

Table 2: Epigenetic Therapeutics Market, Global, Revenue Forecast ($m) 2009–2017 9

Table 3: Epigenetic Therapeutics Market, by Geography, Revenue Forecast ($m) 2009–2017 10

Table 4: Epigenetic therapeutics Market, The US, Revenue Forecast ($m) 2009 - 2017 12

Table 5: Epigenetic Therapeutics Market, Europe, Revenue Forecast ($m), 2009- 2017 13

Table 6: Epigenetic Therapeutics Market, Japan, Revenue Forecast ($m), 2009–2017 15

Table 7: Vidaza – Snapshot, 2010 16

Table 8: Vidaza, Global, Revenue Forecast ($m) 2009–2017 17

Table 9: Vidaza, By Geography, Revenue Forecast ($m )2009 - 2017 18

Table 10: Vidaza, The US, Revenue Forecast ($m) 2009–2017 19

Table 11: Vidaza, Europe, Revenue Forecast ($m), 2009–2017 21

Table 12: Vidaza, Japan, Revenue Forecast ($m), 2009–2017 22

Table 13: Vidaza Market Potential, Global, Revenue Forecast ($m) 2012–2017 24

Table 14: Vidaza Market Potential, By Geography, Revenue Forecast ($m), 2012–2017 25

Table 15: Vidaza Market Potential, The US, Revenue Forecast ($m), 2012–2017 26

Table 16: Vidaza Market Potential, Europe, Revenue Forecast ($m), 2012–2017 27

Table 17: Vidaza Market Potential, Japan, Revenue Forecast ($m), 2012–2017 28

Table 18: Efficacy of Vidaza in MDS Patients, 2010 32

Table 19: Dacogen – Snapshot, 2010 33

Table 20: Dacogen, Global, Revenue Forecast ($m), 2009–2017 34

Table 21: Dacogen, By Geography, Revenue Forecast ($m), 2009–2017 35

Table 22: Dacogen, The US, Revenue Forecast ($m), 2009–2017 36

Table 23: Dacogen, Europe, Revenue Forecast ($m), 2009– 2017 38

Table 24: Dacogen, Japan, Revenue Forecast ($m), 2009–2017 39

Table 25: Dacogen, Market Potential, Global, Revenue Forecast ($m), 2012–2017 40

Table 26: Dacogen Market Potential, By Geography, Revenue Forecast ($m), 2012–2017 41

Table 27: Dacogen, Market Potential, The US, Revenue Forecast ($m), 2012–2017 42

Table 28: Dacogen Market Potential, Europe, Revenue Forecast ($m), 2012–2017 43

Table 29: Dacogen, Market Potential, Japan, Revenue Forecast ($m), 2012–2017 44

Table 30: Zolinza Snapshot, 2010 49

Table 31: Zolinza, Global, Revenue Forecast ($m), 2010–2017 50

Table 32: Zolinza, By Geography, Revenue Forecast ($m), 2010–2017 51

Table 33: Zolinza, The US, Revenue Forecast ($m), 2010–2017 52

Table 34: Zolinza, Europe, Revenue Forecast ($m), 2010–2017 53

Table 35: Zolinza, Japan, Revenue Forecast ($m), 2010–2017 54

Table 36: Zolinza Market Potential, By Geography, Revenue Forecast ($m), 2012–2017 56

Table 37: Zolinza, Market Potential, By Geography, Revenue Forecast ($m), 2012–2017 57

Table 38: Zolinza Market Potential, The US, Revenue Forecast ($m), 2012–2017 58

Table 39: Zolinza Market Potential, Europe, Revenue Forecast ($m), 2012–2017 59

Table 40: Zolinza Market Potential, Japan, Revenue Forecast ($m), 2012–2017 60

Table 41: Istodax Snapshot, 2010 64

Table 42: Istodax Market Potential, By Geography, Revenue Forecast ($m), 2010–2017 66

Table 43: Istodax Market Potential, By Geography, Revenue Forecast ($m), 2012–2017 67

Table 44: Istodax Market Potential, The US, Revenue Forecast ($m), 2010–2017 68

Table 45: Istodax Market Potential, Europe, Revenue Forecast ($m), 2010–2017 69

Table 46: Istodax Market Potential, Japan, Revenue Forecast ($m), 2010–2017 70

1.2 List of Figures

Figure 1: Epigenetic Therapeutics Market, Global, Revenue Forecast ($m) 2009–2017 9

Figure 2: Epigenetic therapeutics Market, by Geography, Revenue Forecast ($m) 2009–2017 10

Figure 3: Epigenetic Therapeutics Market, The US, Revenue Forecast ($m) 2009–2017 11

Figure 4: Epigenetic Therapeutics Market, Europe, Revenue Forecast ($m), 2009–2017 13

Figure 5: Epigenetic Therapeutics Market, Japan, Revenue Forecast ($m) 2009–2017 14

Figure 6: Vidaza, Global, Revenue Forecast ($m) 2009–2017 17

Figure 7: Vidaza, By Geography, Revenue Forecast ($m) 2009–2017 18

Figure 8: Vidaza, The US, Revenue Forecast ($m) 2009–2017 19

Figure 9: Vidaza, Europe, Revenue Forecast ($m) 2009–2017 20

Figure 10: Vidaza, Japan, Revenue Forecast ($m), 2009–2017 22

Figure 11: Vidaza Market Potential, Global, Revenue Forecast ($m), 2012–2017 24

Figure 12: Vidaza Market Potential, By Geography, Revenue Forecast ($m), 2012–2017 25

Figure 13: Vidaza Market Potential, The US, Revenue Forecast ($m), 2012–2017 26

Figure 14: Vidaza Market Potential, Europe, Revenue Forecast ($m), 2012–2017 27

Figure 15: Vidaza Market Potential, Japan, Revenue Forecast ($m), 2012–2017 28

Figure 16: Vidaza (Azacitidine) – Drug Pipeline, by Phase, 2010 29

Figure 17: Vidaza (Azacitidine) – Drug Pipeline, by Indication, 2009 30

Figure 18: Vidaza (Azacitidine) – Drug Pipeline, by Phase and Indication, 2010 31

Figure 19: Dacogen , Global, Revenue Forecast ($m), 2009–2017 34

Figure 20: Dacogen, By Geography, Revenue Forecast ($m), 2009–2017 35

Figure 21: Dacogen, The US, Revenue Forecast ($m), 2009–2017 36

Figure 22: Dacogen, Europe, Revenue Forecast ($m), 2009–2017 37

Figure 23: Dacogen, Japan, Revenue Forecast ($m), 2009–2017 38

Figure 24: Dacogen, Market Potential, Global, Revenue Forecast ($m), 2012–2017 40

Figure 25: Dacogen Market Potential, By Geography, Revenue Forecast ($m), 2012–2017 41

Figure 26: Dacogen Market Potential, The US, Revenue Forecast ($m), 2012–2017 42

Figure 27: Dacogen Market Potential, Europe, Revenue Forecast ($m), 2012–2017 43

Figure 28: Dacogen Market Potential, Japan, Revenue Forecast ($m), 2012–2017 44

Figure 29: Dacogen (Decitabine) – Drug Pipeline, by Phase, 2010 45

Figure 30: Dacogen (Decitabine) – Drug Pipeline, by Indication, 2010 46

Figure 31: Dacogen (Decitabine) – Drug Pipeline, by Phase and Indication, 2010 47

Figure 32: Zolinza, Global, Revenue Forecast ($m), 2010–2017 50

Figure 33: Zolinza, Global, Revenue Forecast ($m), 2010–2017 51

Figure 34: Zolinza, The US, Revenue Forecast ($m), 2010–2017 52

Figure 35: Zolinza, Europe, Revenue Forecast ($m), 2010–2017 53

Figure 36: Zolinza, Japan, Revenue Forecast ($m), 2010–2017 54

Figure 37: Zolinza Market Potential, Global, Revenue Forecast ($m), 2012–2017 56

Figure 38: Zolinza, Market Potential, By Geography, Revenue Forecast ($m), 2012–2017 57

Figure 39: Zolinza Market Potential, The US, Revenue Forecast ($m), 2012–2017 58

Figure 40: Zolinza Market Potential, Europe, Revenue Forecast ($m), 2012–2017 59

Figure 41: Zolinza Market Potential, Japan, Revenue Forecast ($m), 2012–2017 60

Figure 42: Zolinza (vorinostat) – Drug Pipeline, by Phase, 2010 61

Figure 43: Zolinza (vorinostat) – Drug Pipeline, by Indication, 2009 62

Figure 44: Zolinza (vorinostat) – Drug Pipeline, by Phase and Indication, 2010 63

Figure 45: Istodax Market Potential, Global, Revenue Forecast ($m), 2010–2017 66

Figure 46: Istodax Market Potential, By Geography, Revenue Forecast ($m), 2012–2017 67

Figure 47: Istodax Market Potential, The US, Revenue Forecast ($m), 2010–2017 68

Figure 48: Istodax Market Potential, Europe, Revenue Forecast ($m), 2012–2017 69

Figure 49: Istodax Market Potential, Japan, Revenue Forecast ($m), 2012–2017 70

Figure 50: Istodax (Romidepsin) – Drug Pipeline, by Phase, 2010 71

Figure 51: Istodax (Romidepsin) – Drug Pipeline, by Indication, 2010 72

Figure 52: Istodax (Romidepsin) – Drug Pipeline, by Phase and Indication, 2010 73

Figure 53: SWOT, Merck & Co, 2010 77

Figure 54: SWOT, Celgene Corporation, 2010 79

Figure 55: SWOT, Eisai, 2010 82

Figure 56: GBI Research Market Forecasting Model 87

Companies mentioned

Merck & Co

Celgene Corporation

EISAI

To order this report:

Biotechnology Industry: Epigenetics Therapeutics to 2017 – High Market Potential for Epigenetics Drugs in Acute Myeloid Leukemia, Multiple Myeloma and Cutaneous T-Cell Lymphoma

Biotechnology Business News

More Market Research Report

Check our Company Profile, SWOT and Revenue Analysis!

Contact:
Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker

Reportlinker Adds Women's Health Therapeutics, Analysis and Market Forecasts to 2016 - High Unmet Need will Drive the Uptake of Novel Drugs in the Menopause and Osteoporosis Markets

Tue, 31 Aug 2010 16:15:04 +0000

Reportlinker Adds Women's Health Therapeutics, Analysis and Market Forecasts to 2016 - High Unmet Need will Drive the Uptake of Novel Drugs in the Menopause and Osteoporosis Markets

PR Newswire

NEW YORK, Aug. 31 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Women's Health Therapeutics, Analysis and Market Forecasts to 2016 - High Unmet Need will Drive the Uptake of Novel Drugs in the Menopause and Osteoporosis Markets

http://www.reportlinker.com/p0286297/Women's-Health-Therapeutics-Analysis-and-Market-Forecasts-to-2016---High-Unmet-Need-will-Drive-the-Uptake-of-Novel-Drugs-in-the-Menopause-and-Osteoporosis-Markets.html

Women's Health Therapeutics, Analysis and Market Forecasts to 2016 - High Unmet Need will Drive the Uptake of Novel Drugs in the Menopause and Osteoporosis Markets

Summary

GBI Research's report, "Women's Health Therapeutics Market to 2016 - High Unmet Need will Drive the Uptake of Novel Drugs in Menopause and Osteoporosis", provides in-depth analysis of unmet needs, drivers and barriers that impact the global women's health market. The report analyzes the markets for women's health in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales, prices and volumes are forecast until 2016 for the key geographies as well as the leading therapeutic segments. Further, the report provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that shape the global markets.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.

Scope

The Scope of this report includes:

- Annualized market data for the women's health market from 2001 to 2009, forecast forward to 2016.

- Analysis of the leading therapeutic segments, including osteoporosis, hormone therapy for menopause, endometriosis, women's infertility and polycystic ovarian syndrome.

- Analysis of the women's health market in the leading geographies of the world, which include the US, the UK, Germany, France, Italy, Spain and Japan.

- Market characterization of the women's health market, including market size, annual cost of therapy, sales volume and treatment usage patterns.

- Key drivers and barriers that have a significant impact on the market.

- Coverage of pipeline molecules in various phases of drug development.

- Competitive benchmarking of leading companies. The key companies studied in this report are Merck, Pfizer, Johnson & Johnson, Teva Pharmaceuticals and Bayer-Schering Pharma.

- Key M&A activities, licensing agreements, that have taken place in 2009 in the global blood disorders market.

Reasons to buy

The report will enhance your decision making capability. It will allow you to

- Align your product portfolio to the markets with high growth potential.

- Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth.

- Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules with more efficiency and better safety.

- Develop key strategic initiatives by understanding the key focus areas of leading companies.

- Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps.

1 Table of Contents 3

1.1 List of Tables 5

1.2 List of Figures 7

2 Global WH Disorder Therapeutics Market: Introduction 10

2.1 GBI Research Report Guidance 10

3 Global WH Disorder Therapeutics Market: Market Characterization 11

3.1 Introduction 11

3.2 Revenue Forecasts for the Global WH Disorder Therapeutics Market 12

3.2.1 Sales Value 12

3.2.2 Annual Cost of Therapy 13

3.2.3 Treatment Usage Patterns 14

3.2.4 Generics' Share in the Global WH Disorder Therapeutics Market 20

4 Global WH Disorder Therapeutics Market: Therapeutic Landscape 21

4.1 Global Menopause Therapeutics Market 21

4.1.1 Introduction 21

4.1.2 Sales Value 21

4.1.3 Annual Cost of Therapy 23

4.1.4 Treatment Usage Patterns 24

4.1.5 Drivers and Barriers for the Menopause Therapeutics Market 30

4.1.6 Market share by Geography 31

4.1.7 Product Analysis 33

4.2 Global Endometriosis Therapeutics Market 38

4.2.1 Introduction 38

4.2.2 Sales Value 39

4.2.3 Annual Cost of Therapy 40

4.2.4 Treatment Usage Patterns 41

4.2.5 Drivers and Barriers for the Endometriosis Therapeutics Market 46

4.2.6 Market share by Geography 47

4.2.7 Product Analysis 48

4.3 Global Postmenopausal Osteoporosis (PMO) Market 51

4.3.1 Introduction 51

4.3.2 Sales Value 52

4.3.3 Annual Cost of Therapy 53

4.3.4 Treatment Usage Patterns 54

4.3.5 Drivers and Barriers for the Menopause Therapeutics Market 60

4.3.6 Market Share by Geography 61

4.3.7 Product Analysis 63

5 Global WH Disorder Therapeutics Market: Geographical Landscape 68

5.1 Geographical Break-up 68

5.2 The US 71

5.2.1 Sales Value 71

5.2.2 Annual Cost of Therapy 72

5.2.3 Treatment Usage Patterns 73

5.3 Top Five Markets in Europe 78

5.3.1 Sales Value 78

5.3.2 Annual Cost of Therapy 79

5.3.3 Treatment Usage Patterns 80

5.4 Japan 85

5.4.1 Sales Value 85

5.4.2 Annual Cost of Therapy 86

5.4.3 Treatment Usage Patterns 87

6 Global WH Disorder Therapeutics Market: Pipeline Analysis 92

6.1 Introduction 92

6.1.1 Research and Development Pipeline – Menopause 94

6.1.2 Research and Development Pipeline – Endometriosis 96

6.1.3 Research and Development Pipeline - Postmenopausal Osteoporosis 98

6.2 Profiles of Key Late-Stage Drugs in the WH disorder Therapeutics Market 101

6.2.1 Aprela (Bazedoxifene/Conjugated Estrogen) 101

6.2.2 Pristiq (Desvenlaxafine, DVS-233) 102

6.2.3 Visanne 103

6.2.4 Elagolix (NBI-56418) 103

6.2.5 Odanacatib (MK-0822) 104

6.2.6 Viviant (Bazedoxifene) 105

7 Global WH Disorder Therapeutics Market: Competitive Landscape 106

7.1 Market Share Analysis: Women's Health 106

7.2 Competitive Profiling 108

7.2.1 Pfizer Inc 108

7.3 Eli Lilly and Company 109

7.4 Merck & Co. 110

7.5 Procter & Gamble Company 112

7.6 Hoffmann-La Roche Ltd. 114

8 Global WH Disorder Therapeutics Market: Strategic Consolidations 117

8.1 Mergers and Acquisitions 117

8.1.1 Overview 117

8.1.2 Ferring Pharmaceuticals Acquires Global Rights to LYSTEDA from Xanodyne Pharmaceuticals in May 2010 121

8.1.3 BioSante Acquires Elestrin Royalty from Azur Pharma in March 2010 121

8.1.4 Teva-KOWA Pharma Acquires Majority Stake in Taisho Pharmaceutical in February 2010 121

8.1.5 Sciele Pharma Acquires Addrenex Pharmaceuticals in November 2009 121

8.1.6 Warner Chilcott Acquires Prescription Drug Business of Procter & Gamble in October 2009 121

8.1.7 BioSante Pharmaceuticals Merges with Cell Genesys in October 2009 122

8.1.8 Hisamitsu Pharmaceutical Completes Acquisition Of Noven Pharmaceuticals in August 2009 122

8.1.9 Pfizer Acquires Wyeth in January 2009 122

8.1.10 Par Pharmaceuticals Acquires Assets Of Calcitonin & A Manufacturing Facility From MDRNA in April 2009 122

8.2 R&D Licensing Agreements 123

8.2.1 Deals by Indication 123

8.2.2 Deals by Phase 124

8.2.3 Deals by Geography 125

9 Global WH Disorder Therapeutics Market: Appendix 126

9.1 Market Definitions 126

9.2 Abbreviations 126

9.3 Coverage 128

9.3.1 Secondary Research 128

9.3.2 Primary Research 128

9.3.3 Forecasts 129

9.3.4 Expert Panel Validation 131

9.4 Contact Us 131

9.5 Disclaimer 131

9.6 Sources 132

1.1 List of Tables

Table 1: WH Disorder Therapeutics Market, Global, Sales Value ($bn), 2001–2009 12

Table 2: WH Disorder Therapeutics Market, Global, Sales Value ($bn), 2009–2016 13

Table 3: WH Disorder Therapeutics Market, Global, Annual Cost of Therapy ($), 2001–2009 13

Table 4: WH Disorder Therapeutics Market, Global, Annual Cost of Therapy ($), 2009–2016 14

Table 5: WH Disorder Therapeutics Market, Global, Treatment Usage Patterns (in millions), 2001–2009 15

Table 6: WH Disorder Therapeutics Market, Global, Treatment Usage Patterns (in millions), 2009–2016 15

Table 7: WH Disorder Therapeutics Market, Global, Menopause Sales Value ($bn), 2001–2009 22

Table 8: WH Disorder Therapeutics Market, Global, Menopause Sales Value ($bn), 2009–2016 22

Table 9: WH Disorder Therapeutics Market, Global, Menopause Annual Cost of Therapy ($), 2001–2009 23

Table 10: WH Disorder Therapeutics Market, Global, Menopause Annual Cost of Therapy ($), 2009–2016 23

Table 11: WH Disorder Therapeutics Market, Global, Menopause Treatment Usage Patterns (in millions), 2001–2009 25

Table 12: WH Disorder Therapeutics Market, Global, Menopause Treatment Usage Patterns (in millions), 2009–2016 25

Table 13: WH Disorder Therapeutics Market, Global, Endometriosis Sales Value ($bn), 2001–2009 39

Table 14: WH Disorder Therapeutics Market, Global, Endometriosis Sales Value ($bn), 2009–2016 39

Table 15: WH Disorder Therapeutics Market, Global, Endometriosis Annual Cost of Therapy ($), 2001–2009 40

Table 16: WH Disorder Therapeutics Market, Global, Endometriosis Annual Cost of Therapy ($), 2009–2016 40

Table 17: WH Disorder Therapeutics Market, Global, Endometriosis Treatment Usage Patterns (in millions), 2001–2009 41

Table 18: WH Disorder Therapeutics Market, Global, Endometriosis Treatment Usage Patterns (in millions), 2009–2016 42

Table 19: WH Disorder Therapeutics Market, Global, PMO Sales Value ($bn), 2001–2009 52

Table 20: WH Disorder Therapeutics Market, Global, PMO Sales Value ($bn), 2009–2016 52

Table 21: WH Disorder Therapeutics Market, Global, PMO Annual Cost of Therapy ($), 2001–2009 53

Table 22: WH Disorder Therapeutics Market, Global, PMO Annual Cost of Therapy ($), 2009–2016 54

Table 23: WH Disorder Therapeutics Market, Global, PMO Treatment Usage Patterns (in millions), 2001–2009 55

Table 24: WH Disorder Therapeutics Market, Global, PMO Treatment Usage Patterns (in millions), 2009–2016 55

Table 25: WH Disorder Therapeutics Market, Global, Sales Value by Geography ($bn), 2001–2009 69

Table 26: WH Disorder Therapeutics Market, Global, Sales Value by Geography ($bn), 2009–2016 69

Table 27: WH Disorder Therapeutics Market, The US, Sales Value ($bn), 2001–2009 71

Table 28: WH Disorder Therapeutics Market, The US, Sales Value ($bn), 2009–2016 71

Table 29: WH Disorder Therapeutics Market, The US, Annual Cost of Therapy ($), 2001–2009 72

Table 30: WH Disorder Therapeutics Market, The US, Annual Cost of Therapy ($), 2009–2016 72

Table 31: WH Disorder Therapeutics Market, The US, Treatment Usage Patterns (in millions), 2001–2009 73

Table 32: WH Disorder Therapeutics Market, The US, Treatment Usage Patterns (in millions), 2009–2016 74

Table 33: WH Disorder Therapeutics Market, Top Five Markets in Europe, Sales Value ($bn), 2001–2009 78

Table 34: WH Disorder Therapeutics Market, Top Five Markets in Europe, Sales Value ($bn), 2009–2016 78

Table 35: WH Disorder Therapeutics Market, Top Five Markets in Europe, Annual Cost of Therapy ($), 2001–2009 79

Table 36: WH Disorder Therapeutics Market, Top Five Markets in Europe, Annual Cost of Therapy ($), 2009–2016 79

Table 37: WH Disorder Therapeutics Market, Top Five Markets in Europe, Treatment Usage Pattern (in millions), 2001–2009 80

Table 38: WH Disorder Therapeutics Market, Top Five Markets in Europe, Treatment Usage Pattern (in millions), 2009–2016 81

Table 39: WH Disorder Therapeutics Market, Japan, Sales Value ($bn), 2001–2009 85

Table 40: WH Disorder Therapeutics Market, Japan, Sales Value ($bn), 2009–2016 85

Table 41: WH Disorder Therapeutics Market, Japan, Annual Cost of Therapy ($), 2001–2009 86

Table 42: WH Disorder Therapeutics Market, Japan, Annual Cost of Therapy ($), 2009–2016 86

Table 43: WH Disorder Therapeutics Market, Japan, Treatment Usage Pattern (in millions), 2001–2009 87

Table 44: WH Disorder Therapeutics Market, Japan, Treatment Usage Pattern (in millions), 2009–2016 88

Table 45: WH Disorder Therapeutics Market, Global, R&D Pipeline by Phase in Menopause Market, Phase III Pipeline, August 2010 95

Table 46: WH Disorder Therapeutics Market, Global, R&D Pipeline by Phase in Menopause Market, Phase II Pipeline, August 2010 95

Table 47: WH Disorder Therapeutics Market, Global, R&D Pipeline by Phase in Menopause Market, Phase I Pipeline, August 2010 95

Table 48: WH Disorder Therapeutics Market, Global, R&D Pipeline by Phase in Menopause Market, Preclinical Pipeline, August 2010 96

Table 49: WH Disorder Therapeutics Market, Global, R&D Pipeline by Phase in Endometriosis Market, Phase III and Regulatory Filing, August 2010 97

Table 50: WH Disorder Therapeutics Market, Global, R&D Pipeline by Phase in Endometriosis Market, Phase II Pipeline, August 2010 97

Table 51: WH Disorder Therapeutics Market, Global, R&D Pipeline by Phase in Endometriosis Market, Phase I Pipeline, August 2010 97

Table 52: WH Disorder Therapeutics Market, Global, R&D Pipeline by Phase in Endometriosis Market, Preclinical Pipeline, August 2010 97

Table 53: WH Disorder Therapeutics Market, Global, R&D Pipeline by Phase in Postmenopausal Osteoporosis Market, Phase III and Regulatory Filing, August 2010 99

Table 54: WH Disorder Therapeutics Market, Global, R&D Pipeline by Phase in Postmenopausal Osteoporosis Market, Phase II Pipeline, August 2010 99

Table 55: WH Disorder Therapeutics Market, Global, R&D Pipeline by Phase in Postmenopausal Osteoporosis Market, Phase I Pipeline, August 2010 99

Table 56: WH Disorder Therapeutics Market, Global, R&D Pipeline by Phase in Postmenopausal Osteoporosis Market, Preclinical Pipeline, August 2010 100

Table 57: WH Disorder Therapeutics Market, Global, Major M&A Deals, 2009–2010 120

1.2 List of Figures

Figure 1: Women's Health Market, Global, Drivers and Restraints, 2009 11

Figure 2: WH Disorder Therapeutics Market, Global, Sales Value ($bn), 2001–2016 12

Figure 3: WH Disorder Therapeutics Market, Global, Annual Cost of Therapy ($), 2001–2016 13

Figure 4: WH Disorder Therapeutics Market, Global, Therapeutic Usage Patterns, 2001–2016 14

Figure 5: WH Disorder Therapeutics Market, Global, Diseased Population (in millions), 2001–2016 16

Figure 6: WH Disorder Therapeutics Market, Global, Treatment Seeking Population (in millions), 2001–2016 17

Figure 7: WH Disorder Therapeutics Market, Global, Diagnosed Population (in millions), 2001–2016 18

Figure 8: WH Disorder Therapeutics Market, Global, Prescription Population (in millions), 2001–2016 19

Figure 9: WH Disorder Therapeutics Market, Global, Branded v/s Generic Drugs, $bn, 2001–2016 20

Figure 10: WH Disorder Therapeutics Market, Global, Menopause Sales Value ($bn), 2001–2016 22

Figure 11: WH Disorder Therapeutics Market, Global, Menopause Annual Cost of Therapy ($), 2001–2016 23

Figure 12: WH Disorder Therapeutics Market, Global, Menopause Treatment Usage Patterns (million), 2001–2016 24

Figure 13: WH Disorder Therapeutics Market, Global, Menopause Diseased Population (in millions), 2001–2016 26

Figure 14: WH Disorder Therapeutics Market, Global, Menopause Treatment Seeking Population (in millions), 2001–2016 27

Figure 15: WH Disorder Therapeutics Market, Global, Menopause Diagnosis Population (in millions), 2001–2016 28

Figure 16: WH Disorder Therapeutics Market, Global, Menopause Prescription Population (in millions), 2001–2016 29

Figure 17: WH Disorder Therapeutics Market, Global, Menopause, Market Segmentation by Geography, 2009 and 2016 31

Figure 18: WH Disorder Therapeutics Market, Global, Menopause, Market Segmentation by Geography, 2001 - 2016 32

Figure 19: WH Disorder Therapeutics Market, Global, Endometriosis Sales Value ($bn), 2001–2016 39

Figure 20: WH Disorder Therapeutics Market, Global, Endometriosis Annual Cost of Therapy ($), 2001–2016 40

Figure 21: WH Disorder Therapeutics Market, Global, Endometriosis Treatment Usage Patterns (million), 2001–2016 41

Figure 22: WH Disorder Therapeutics Market, Global, Endometriosis Diseased Population (in millions), 2001–2016 42

Figure 23: WH Disorder Therapeutics Market, Global, Endometriosis Treatment Seeking Population (in millions), 2001–2016 43

Figure 24: WH Disorder Therapeutics Market, Global, Endometriosis Diagnosis Population (in millions), 2001–2016 44

Figure 25: WH Disorder Therapeutics Market, Global, Endometriosis Prescription Population (in millions), 2001–2016 45

Figure 26: WH Disorder Therapeutics Market, Global, Endometriosis, Market Segmentation by Geography, 2009 and 2016 47

Figure 27: WH Disorder Therapeutics Market, Global, Endometriosis, Market Segmentation by Geography, 2001 - 2016 48

Figure 28: WH Disorder Therapeutics Market, Global, PMO Sales Value ($bn), 2001–2016 52

Figure 29: WH Disorder Therapeutics Market, Global, PMO Annual Cost of Therapy ($), 2001–2016 53

Figure 30: WH Disorder Therapeutics Market, Global, PMO Treatment Usage Patterns (in millions), 2001–2016 54

Figure 31: WH Disorder Therapeutics Market, Global, PMO Diseased Population (in millions), 2001–2016 56

Figure 32: WH Disorder Therapeutics Market, Global, PMO Treatment Seeking Population (in millions), 2001–2016 57

Figure 33: WH Disorder Therapeutics Market, Global, PMO Diagnosis Population (in millions), 2001–2016 58

Figure 34: WH Disorder Therapeutics Market, Global, PMO Prescription Population (in millions), 2001–2016 59

Figure 35: WH Disorder Therapeutics Market, Global, PMO, Market Segmentation by Geography, 2009 and 2016 61

Figure 36: WH Disorder Therapeutics Market, Global, PMO, Market Segmentation by Geography, 2009–2016 62

Figure 37: WH Disorder Therapeutics Market, Global, Market Share by Geography, 2009 and 2016 68

Figure 38: WH Disorder Therapeutics Market, Global, Sales Value by Geography ($bn), 2001–2016 69

Figure 39: WH Disorder Therapeutics Market, Global, Geography Benchmarking, 2009 and 2016 70

Figure 40: WH Disorder Therapeutics Market, US, Sales Value ($bn), 2001–2016 71

Figure 41: WH Disorder Therapeutics Market, The US, Annual Cost of Therapy ($), 2001–2016 72

Figure 42: WH Disorder Therapeutics Market, The US, Treatment Usage Patterns (in millions), 2001–2016 73

Figure 43: WH Disorder Therapeutics Market, The US, Diseased Population (in millions), 2001–2016 74

Figure 44: WH Disorder Therapeutics Market, The US, Treatment Seeking Population (in millions), 2001–2016 75

Figure 45: WH Disorder Therapeutics Market, The US, Diagnosis Population (in millions), 2001–2016 76

Figure 46: WH Disorder Therapeutics Market, The US, Prescription Population (in millions), 2001–2016 77

Figure 47: WH Disorder Therapeutics Market, Top Five Markets in Europe, Sales Value ($bn), 2001–2016 78

Figure 48: WH Disorder Therapeutics Market, Top Five Markets in Europe, Annual Cost of Therapy ($), 2001–2016 79

Figure 49: WH Disorder Therapeutics Market, Top Five Markets in Europe, Treatment Usage Patterns (in millions), 2001–2016 80

Figure 50: WH Disorder Therapeutics Market, Top Five Markets in Europe, Diseased Population (in millions), 2001–2016 81

Figure 51: WH Disorder Therapeutics Market, Top Five Markets in Europe, Treatment Seeking Population (in millions), 2001–2016 82

Figure 52: WH Disorder Therapeutics Market, Top Five Markets in Europe, Diagnosis Population (in millions), 2001–2016 83

Figure 53: WH Disorder Therapeutics Market, Top Five Markets in Europe, Prescription Population (in millions), 2001–2016 84

Figure 54: WH Disorder Therapeutics Market, Japan, Sales Value ($m), 2001–2016 85

Figure 55: WH Disorder Therapeutics Market, Japan, Annual Cost of Therapy ($), 2001–2016 86

Figure 56: WH Disorder Therapeutics Market, Japan, Treatment Usage Pattern (in millions), 2001–2016 87

Figure 57: WH Disorder Therapeutics Market, Japan, Diseased Population (in millions), 2001–2016 88

Figure 58: WH Disorder Therapeutics Market, Japan, Treatment Seeking Population (in millions), 2001–2016 89

Figure 59: WH Disorder Therapeutics Market, Japan, Diagnosed Population (in millions), 2001–2016 90

Figure 60: WH Disorder Therapeutics Market, Japan, Prescription Population (in millions), 2001–2016 91

Figure 61: WH Disorder Therapeutics Market, Global, R&D Pipeline by Indication (%), August 2010 92

Figure 62: WH Disorder Therapeutics Market, Global, R&D Pipeline by Phase (%), August 2010 93

Figure 63: WH Disorder Therapeutics Market, Global, R&D Pipeline by Phase in Menopause Market (%), August 2010 94

Figure 64: WH Disorder Therapeutics Market, Global, R&D Pipeline by Phase in the Endometriosis Therapeutics Market (%), August 2010 96

Figure 65: WH Disorder Therapeutics Market, Global, R&D Pipeline by Phase in Postmenopausal Osteoporosis Market (%), August 2010 98

Figure 66: WH Disorder Therapeutics Market, Global, Market Share of Top Manufacturers (%), 2009 106

Figure 67: WH Disorder Therapeutics Market, Global, Revenue of Top Five Players ($m), 2009 107

Figure 68: WH Disorder Therapeutics Market, Global, Average value, Revenue of Top Five Players ($m), 2009 107

Figure 69: WH Disorder Therapeutics Market, SWOT Analysis, Pfizer, 2009 109

Figure 70: WH Disorder Therapeutics Market, SWOT Analysis, Eli Lilly, 2009 110

Figure 71: WH Disorder Therapeutics Market, SWOT Analysis, Merck, 2009 111

Figure 72: WH Disorder Therapeutics Market, SWOT Analysis, Procter & Gamble, 2009 113

Figure 73: WH Disorder Therapeutics Market, SWOT Analysis, Hoffman-La Roche, 2009 116

Figure 74: WH Disorder Therapeutics Market, Global, M&A Deals by Indication (%), 2004-2010 117

Figure 75: WH Disorder Therapeutics Market, Global, M&A Deals by Deal Type (%), 2009 118

Figure 76: WH Disorder Therapeutics Market, Global, M&A Deals by Deal Value (%), 2009 119

Figure 77: WH Disorder Therapeutics Market, Global, Major Licensing Agreements By Indication (%), 2004–2010 123

Figure 78: WH Disorder Therapeutics Market, Global, Major Licensing Agreements By Phase (%), 2004–2010 124

Figure 79: WH Disorder Therapeutics Market, Global, Major Licensing Agreements By Geography (%), 2009–2010 125

Figure 80: GBI Research Market Forecasting Model, 2010 130

Companies mentioned

Eli Lilly and Company

Merck & Co.

Procter & Gamble Company

Hoffmann-La Roche Ltd.

Pfizer Inc

To order this report:

Pathology Industry: Women's Health Therapeutics, Analysis and Market Forecasts to 2016 - High Unmet Need will Drive the Uptake of Novel Drugs in the Menopause and Osteoporosis Markets

Pathology Business News

More Market Research Report

Check our Company Profile, SWOT and Revenue Analysis!

Contact:
Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker

Reportlinker Adds E7: The Outlook for Pharmaceuticals to 2012

Tue, 31 Aug 2010 15:59:16 +0000

Reportlinker Adds E7: The Outlook for Pharmaceuticals to 2012

PR Newswire

NEW YORK, Aug. 31 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

E7: The Outlook for Pharmaceuticals to 2012

http://www.reportlinker.com/p0192576/E7-The-Outlook-for-Pharmaceuticals-to-2012.html

The E7 economies represent increasing opportunities for pharmaceutical companies constrained by maturing markets in the west.

Less reliance on mature markets

A report from PricewaterhouseCoopers (Pharma 2020: The vision: Which path will you take?) highlighted the dangers for the pharmaceutical industry of relying on existing mature markets such as the USA in the period to 2020. Pressures on pricing and greater payor influence will reduce the relative profitability of the USA, meaning that the industry will do well to look elsewhere for growth.

Huge potential in E7 markets

The emerging 'E7' countries represent the best prospect for growth. The potential of these countries is huge: they have a combined population of over three billion people, and their economies are recovering from the economic downturn. One consequence of this increasing wealth is a growing financial capacity to treat previously unmet health needs. Another is increasing incidence of 'affluence' diseases such as diabetes, as people live longer and have more sedentary lifestyles.

Highlights from the report

BRAZIL

Brazil is the second most attractive BRIC market for pharmaceutical producers. Controlled drug prices are growing at below inflational levels but price controls are not directly linked to consumption levels. In fact, between 1997 and 2008, the pharmaceutical market by volume increased significantly only in 2004. Demand should increase as the country is emerging from the economic downturn much quicker than anticipated, therefore the outlook is very positive compared to other Latin American markets. The exchange rate of the real against the US dollar fell in early 2009, but it has now recovered. This is good news for producers as imports are now cheaper; Brazil, in contrast with other BRIC countries such as India, still relies on raw material imports, which diminishes its market strength.

CHINA

China's pharmaceutical market looks set to grow even further in the short-term, with the establishment of an Essential Medicines System during the 2009-2011 period. The plan calls for an estimated 300-400 essential medicines to be made available at all public facilities, starting at the grassroots level. In October 2009, the NDRC reduced the prices of 2,349 drugs by an average 12%. These drugs represent around 45% of drugs on the Essential Medicines System. The prices of 49% of drugs on the list will not be reduced while the remaining 6% that are in short supply will see their prices increased moderately in order to encourage their manufacture.

INDIA

India has a huge population in excess of one billion people and a growing middle class with access to high quality healthcare. Conversely, in this geographically vast country plagued by natural disasters, the majority of the population is both rural and poor and western style pharmaceuticals are not even an issue for millions of people. India has an established domestic industry, responsible for around 8% of world pharmaceutical production. The larger domestic companies are striving to compete in the global market for both generics and original products. The market is dominated by low priced, domestically-produced generics and relatively low per capita expenditure on pharmaceuticals.

INDONESIA

The domestic pharmaceutical manufacturing industry is strong and the country has become an attractive base for many multinational producers to operate. This is largely down to a cheap labour force and generally inexpensive production costs. In March 2009, the government announced the merger between PT Indofarma and PT Kimia, saying the partnership, once materialised, will enable them to control a 15% stake of the market. PT Kimia president Sjamsul Ariffin said feasibility studies and legal processes would take at least six to nine months before the merger can be finalised. IPR protection is generally regarded as inadequate and counterfeiting is a major problem. The country has been placed on the US government's Priority Watch List in 2009.

MEXICO

The current exchange rate of the Mexican peso against the US dollar is causing uncertainty, with increasing pharmaceutical import costs. This is expected to affect previously registered import levels. The overall pharmacy sector is facing stagnation, if not negative growth, in 2009. Pfizer's acquisition of Wyeth and the merger of Merck Sharp & Dohme and Schering Plough will change the sector, with sanofi-aventis being pushed down. On a positive note, the downturn and an evolving regulatory environment are fuelling generics consumption. This market is expected to double in size in 2010. The latest foreign company to enter the generic market is Valeant which acquired a local producer in July 2009; sanofi-aventis acquired a local producer in early 2009. The local company Genomma Lab launched its generic product portfolio in August 2009.

RUSSIA

In population terms, Russia is a potentially vast market. Health spending is generally very low, however, in comparison with Western countries. Around 75% of the pharmaceutical market is supplied by imports. The domestic generic industry is sizeable, but the local production of innovative drugs is negligible. Russian manufacturers are small and under-funded, often making do with outdated equipment. The market environment remains challenging for overseas companies. Major problems reported in Russia include corruption, bureaucracy, counterfeiting and poor data confidentiality. Government officials and politicians often discriminate in favour of the domestic industry, and enforcement of existing rules is often weak.

TURKEY

As part of Turkey's bid to join the EU, national legislation regarding pharmaceutical regulation is becoming more aligned with that of the EU. Partly as a result of previous efforts, but also of this harmonisation, the regulatory environment in Turkey is far more complex and the processes much more comprehensive in Turkey than elsewhere in the Middle East. However, there are still concerns within the international community over Turkey's poor patent protection and intellectual property provision. Turkey has a considerable number of domestic producers, including Abdi Ibrahim, Bilim Pharmaceuticals, Eczacibasi, Embil Pharmaceutical Company, Fako Ilaclari, Milen Pharmaceuticals, Mustafa Nevzat Pharmaceuticals, Sanovel and the Turgut Group.

To order this report:

Pharmaceutical Industry: E7: The Outlook for Pharmaceuticals to 2012

Pharmaceutical Business News

More Market Research Report

Check our Company Profile, SWOT and Revenue Analysis!

CONTACT:

Nicolas Bombourg

Reportlinker

Email: nbo@reportlinker.com

US: (805)652-2626

Intl: +1 805-652-2626

SOURCE Reportlinker